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Abstract  
 
 
Both, the cytokine Tumor Necrosis Factor-α (TNF-α) and the enzyme cytosolic 
phospholipase A2 (cPLA2) are crucial driving forces in mediating the cellular 
inflammatory response and are involved in ischaemic injury. During an ischaemic 
insult, TNF-α is endogenously generated. Apart from the recognized effects of TNF-
α, such as the induction of apoptosis, proliferation and differentiation, if present in 
low dosages, it also mediates cytoprotective effects. Upon activation, cPLA2 
contributes to the ischaemic challenge with the generation of mediators of cellular 
injury and apoptosis. Upon stimulation, this calcium dependent enzyme translocates 
to the phospholipid compartment of the cell membrane and induces the hydrolysis of 
sn-2 ester bonds in phospholipids. It governs the release of free fatty acids and 
lysophospholipids and generates role players of inflammation. We suggest a role for 
cPLA2 in the TNF-α mediated cytoprotection, with a distinct phosphorylation and 
translocation pattern. 
 
Aims 
The involvement of cPLA2 in TNF-α mediated cytoprotection in the C2C12 murine 
skeletal muscle cell line in tolerance to ischaemia was examined. To investigate the 
nature of the cPLA2 phosphorylation pattern, the mitogen activated protein kinases 
(MAPKs) p38 and extracellular regulated kinase (ERK) as contributors to cPLA2 
phosphorylation and activation, were examined at appropriate time points. To dissect 
out the cPLA2 interplay and dependencies with these MAPKs within the pathway 
context, the selective cPLA2 inhibitor arachidonyl trifluoromethyl ketone (AACOCF3) 
was employed and its effect on cell viability was examined. Fluorescence microscopy 
was used to substantiate cPLA2 activation, by assessing its cellular distribution, 
translocation and cell organelle target preference, using co-localization and z-stack 
techniques. In addition, the induction of the apoptotic pathway through analysis of 
caspase-3 and poly (ADP-ribose) polymerase (PARP) cleavage was examined. The 
role of caspase-3 in cPLA2 turnover was addressed employing the caspase inhibitor, 
Z-DEVD-FMK.  
 
 
 iv
Methods 
Cells were grown in Dulbecco’s Modified Eagles Medium (DMEM) with 10% fetal 
bovine serum (FBS), and incubated under 5% CO2 conditions, until 50%-70% 
confluent. Using DMEM supplemented with 1% horse serum, cell differentiation into 
myotubes was induced. Differentiated cells were preconditioned for 30 min 
classically, with 0.5 ng/ml TNF-α or the cPLA2 selective inhibitor AACOCF3 (10 
µM) respectively.  Followed by a 60 min washout period the cells were subjected to 8 
hrs simulated ischaemia. Cellular viability; and cPLA2 phosphorylation- and 
translocation events were assessed using Western blots and advanced 
immunocytochemistry and imaging techniques.  
 
Results  
Preconditioning with TNF-α, ischaemic preconditioning; and the use of the cPLA2 
inhibitor AACOCF3, attenuated the decrease is cell viability brough about by 
ischaemia. Western blot analysis indicates the induction of the apoptotic pathway with 
caspase-3 and PARP cleavage. A significantly reduced translocation of pcPLA2 to the 
nuclear region in the TNF-α preconditioned group compared to the ischaemic group, 
as reflected by reduced mean nuclear fluorescence intensity, was observed. A z-stack 
analysis confirmed that the nuclear and endonuclear region was the target organelle 
for cPLA2. 3-dimensional co-localazation analysis of pcPLA2 with the nuclear marker 
nucleoporin p62 mirrored these results. 
 
Discussion and conclusion 
Our results provide evidence that there is a role for cPLA2 in TNF-α mediated 
cytoprotection. Although we do not observe a differential activation pattern in terms 
of cPLA2 phosphorylation at various time points within the ischaemic event, and no 
differential inactivation of cPLA2 via caspase-mediated cPLA2 cleavage, we describe 
a differential cPLA2 translocation pattern, similar to that in IPC. Through inhibition of 
cPLA2 translocation, a functional cPLA2 inhibition might be achieved. This would 
imply inhibition of the inflammatory pathway and a subsequent reduction in the 
generation of inflammatory mediators. In addition we describe an effect of TNF-α 
preconditioning on the efficacy of the caspase inhibitor Z-DEVD-FMK. Our results 
 v
shed light on the survival mechanisms employed by the ischaemically challenged cell 
in a setting of TNF-α mediated cytoprotection. This might lead to novel approaches in  
the context of inflammation treatment, through agents that control differential cPLA2 
trafficking within the cell.  
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Opsomming  
 
 
Beide, die sitokien “Tumor Necrosis Factor-α (TNF-α)” en die ensiem, sitosoliese 
fosfolipase A2 (cPLA2) is uiters belangrike bemiddelaars van die sellulêre 
inflammatoriese respons en is verder ook betrokke by isgemiese selskade. TNF-α 
word endogeen gegenereer tydens ‘n isgemiese intervensie. Afgesien van ‘n 
verskeidenheid effekte, soos die inisiëring van apoptose, sel-proliferasie en -
differensiasie, bemiddel dit ook selbeskermende meganismes indien dit in lae 
konsentrasies in die sel teenwoordig is. Na aktivering dra cPLA2 by tot die isgemiese 
intervensie deur die vorming van bemiddelaars van selskade en apoptose. Hierdie 
kalsium-afhanklike ensiem translokeer na die fosfolipied membraankomponent na 
stimulering en induseer die hidrolise van die sn-2 esterbinding in die fosfolipied. Die 
vrystelling van vry vetsure en lisofosfolipiede word sodoende bewerkstellig wat 
verder gemetaboliseer kan word tot inflammatoriese bemiddelaars. Ons stel voor dat 
cPLA2 ‘n rol in TNF-α bemiddelde selbeskerming speel en dat dit gepaardgaan met 
kenmerkende fosforilerings- en translokeringspatrone.  
 
Doelwitte 
Die rol van cPLA2 tydens TNF-α bemiddelde selbeskerming is in ‘n C2C12 
skeletspiersellyn na blootstelling aan isgemie ondersoek. Die rol van die MAPKs, p38 
en ERK, is ondersoek om vas te stel of hulle betrokke is by die aktivering van cPLA2. 
Die selektiewe cPLA2 inhibitor, AACOCF3, is gebruik om te bepaal of die 
fosforilering van MAPKs ook cPLA2-afhanklik is. Die sellulêre cPLA2 verspreiding, 
translokering en teiken selorganelle is ook ondersoek met behulp van fluoresensie 
mikroskopie deur gebruik te maak van ko-lokalisering en z-plaat tegnieke. Verder, is 
die indusering van die apoptotiese paaie ondersoek deur tegnieke wat kaspase- en 
PARP kliewing meet. Die kaspase inhibitor, Z-DEVD-FMK, is gebruik om vas te stel 
of kaspase-3 ‘n rol speel in cPLA2 kliewing in ons selmodel.  
 
Metodes 
Selle is gekweek in Dulbecco’s gemodifiseerde Eagles Medium (DMEM) waarby 
10% fetale kalf serum (FBS) gevoeg is, en wat geïnkubeer is in 5% CO2 totdat dit 
50%-70% konfluent was. Die selle is verder gedifferensieer in miobuise deur gebruik 
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te maak van DMEM waarby 1% perdeserum gevoeg is. Gedifferensieerde selle is vir 
30 min klassiek geprekondisioneer asook respektiewelik met 0.5 ng/ml TNF-α en die 
cPLA2 selektiewe inhibitor, AACOCF3 (10 µM).  Na ‘n 60 minute uitwas periode is 
die selle blootgestel aan 8 h gesimuleerde isgemie. Sellulêre lewensvatbaarheid, 
cPLA2 fosforilering- and translokering is ondersoek deur onderskeidelik gebruik te 
maak van die “Western” klad metode en gesofistikeerde immunositochemiese beeld 
tegnieke.  
 
Resultate  
Prekondisionering met TNF-α, isgemiese prekondisionering asook inhibisie van as 
cPLA2 met die inhibitor, AACOCF3, het ‘n beduidende toename in 
sellewensvatbaarheid tot gevolg gehad. Daar is ook dmv die “Western” klad tegniek 
bewys dat apoptose geïduseer word deur middel van kaspase-3- en PARP kliewing. 
Daar is insiggewend minder translokasie van cPLA2 na die nukluêre fraksie in die 
isgemiese groep in vergelyking met die TNF-α geprekondisioneerde groep 
waargeneem (die gemiddelde nukluêre fluoreserende intensiteit is bepaal om 
voorafgaande feit te staaf). Die cPLA2 teiken organel is geverifieer as die nukleus en 
die endonukluêre gebied deur middel van z-plaat analises. Drie-dimensionele ko-
lokaliserings analises van pcPLA2 met die nukluêre merker, nucleoporin p62 het 
hierdie resultate bevestig. 
 
Bespreking en Gevolgtrekking 
Ons resultate verskaf bewyse vir ‘n rol vir cPLA2 in TNF-α bemiddelde 
selbeskerming. Alhoewel daar nie ‘n differensiële aktiveringspatroon in terme van 
cPLA2 fosforilering tydens verskeie tydspunte in die isgemiese intervensie 
waargeneem is nie, en ook geen kaspase-3 bemiddelde kliewing van cPLA2 nie, word 
‘n differensiële translokeringspatroon soorgelyk aan die isgemiese 
prekondisioneringsgroep, waargeneem. Funsksionele cPLA2 inhibisie kan dus 
moontlik bewerkstellig word deur inhibisie van cPLA2 translokasie. Die 
inflammatoriese respons kan dus moontlik so inhibieer word en die vorming van 
minder inflammatoriese bemiddelaars tot gevolg hê. Verder het TNF-α 
prekondisionering ook ‘n effek op die effektiwiteit van die kaspase-inhibitor, Z-
DEVD-FMK. Ons resultate werp ook lig op die meganismes wat deur selle onder 
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isgemiese toestande uitgeoefen word tydens TNF-α bemiddelde selbeskerming. 
Hierdie resultate mag lei tot nuwe benaderings in die konteks van behandeling teen 
inflammasie deur gebruik te maak van middels wat cPLA2 translokering in die sel 
beheer.  
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Zusammenfassung 
 
 
Das Zytokin Tumor Necrosis Factor- α (TNF-α) und das Enzym zytosolische 
Phospholipase A2 (cPLA2) sind wichtige Rollenspieler in der zellulären 
Entzündungsantwort und sind beide involviert in Gwebeischemie. Während einer 
ischemischen Attacke ist  TNF-α in der Zelle generiert. Abgesehen von verschiedenen 
Effekten, wie die Induction von Apoptosis, Zellteilung und Zelldifferenzierung, wenn 
anwesend in geringen Konzentrationen, hat  TNF-α einen zellschützenden Effekt. 
cPLA2 nimmt an der ischemischen Herausforderung teil, durch die Herstellung von 
Mediatoren der Zellverletzung und des apoptotischen Zelltodes. Wenn stimmuliert, 
translokiert dieses Calcium-abhängige Enzym zu Phospholipidmembrankomponenten 
und induziert dort die Hydrolisierung von Esterverbindungen im Phospholipid. Es 
kontrolliert die Freilassung von freien Fettsäuren und Lysophospholipiden und stellt 
Entzündungsmediatoren durch Arachidonsäure her. Wir stellen eine Rolle für cPLA2, 
mit einem spezifischen Phosphorilierungs-und Translokierungsmuster im TNFα 
vermittelten Zellschutz vor.  
 
Ziel 
Wir untersuchten die Beteiligung von cPLA2 im TNFα vermittelten Zellschutz in der 
C2C12 Muskelzelllinie in Toleranz zu Ischemie. Um die Natur des cPLA2 
Phosphorilierungsmusters zu beschreiben, wurden die MAPK p38 und ERK als 
Beisteuerer zur cPLA2 Phosphorilierung und Aktivierung zu bestimmten Zeitpunkten 
untersucht. Um das Zwischenspiel und die Abhängigkeiten bezüglich der MAPK im 
Pfadwegkontext zu beurteilen, wurde der selektive  cPLA2 Unterdrücker AACOCF3 
verwendet, und sein Effekt auf Zellviabilität untersucht. Die Aktivierung von cPLA2 
wurde untermalt durch die fluoreszenmikroskopische Beobachtung von zellulärer 
Verteilung, Translokation und Zielorganelpreffernez, unter Verwendung von Ko-
lokalisierungs-und Z-schicht technik. Zusätzlich beurteilten wir die Induktion vom 
apoptotischen Zelltod, durch die Analysierung von Caspase-3 und PARP Zerteilung. 
Caspase-3 verwandte Kontrolle über  cPLA2 wurde durch die Benutzung vom Caspase 
Unterdrücker Z-DEVD-FMK addressiert.  
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Methodik 
Zellen wurden in Dulbecos Modified Eagles Medium (DMEM) mit 10% fötalem 
bovine Serum (FBS) gezüchtet und unter 5 % CO2 inkubiert, bis eine Konfluenz von 
50%-70% erreicht war. Unter Verwendung von DMEM mit 1% Pferdeserum wurde 
Zelldifferenzierung in Muskeltuben induziert. Differenzierte Zellen wurden für 30 
min klassisch, mit 0.5ng/ml TNF-α, oder mit dem selektiven cPLA2 Unterdrücker 
AACOCF3 (10µM) pre-konditioniert. Gefolgt von einer 60 minütigen 
Auswaschperiode, wurden die Zellen einer 8 stündigen simulierten Ischemie 
ausgesetzt.  Untersucht wurden Zellviabilität, cPLA2 Phosphorilierungs- und 
Translokierungsvorgänge unter Verwendung von Western Blot- und vortgeschrittener 
immunzytochemischen Bild-technik. 
 
Ergebnisse 
Pre-Konditionierung mit TNF-α, ischemische Pre-Konditionierung und die 
Verwendung des cPLA2 Unterdrückers AACOCF3, resultierten in eine signifikante 
Erhöhung der Zellviabilität.  Western blot Analyse erwiesen die Induktion des 
apoptotischen Pfadweges mit Caspase-3 und PARP Zerteilung. Wir beschreiben eine 
signifikant reduzierte Translokierung von  pcPLA2 zur nukleären Region in der TNF-
α-pre-konditionierten Zellgruppe vergichen mit ischemischen Zellen, was in einer 
reduzierten mitleren nukleären Fluoreszenintensität reflektiert wird.  Die Z-schicht 
Analyse verifiziert eine nukleäre und innernukleäre Region als cPLA2 Zielorganell. 
Dreidimensionelle Ko-lokalisierungsanalyse von pcPLA2 mit dem nuleären Marker 
nucleoporin p62 spiegelt diese Ergebnisse wieder.  
 
Diskussion und Schlussfolgerung 
Unsere Ergebnisse liefern Beweis für eine Rolle von  cPLA2 im TNF-α-vermittelten 
Zellschutz.  Obwohl wir kein differenziertes Aktivierungsmuster beobachten, im 
Sinne von cPLA2 Phosphorilierung zu verschiedenen Zeitpunkten innerhalb der 
ischemischen Attacke, und keine differenzielle  cPLA2 Inaktivierung durch Caspase 
vermittelte cPLA2 Zerteilung, so beschreiben wir jedoch ein differenziertes 
Translokationsmuster, gleichend dem in klassischer Pre-konditionierung.  Durch die 
Unterdrückung der innerzellulären cPLA2 Bewegung  könnte eine funktionelle cPLA2 
Unterdrückung resultieren. Dies würde eine Unterdrückung des 
 xi
Enzündungspfadweges implizieren, folgend von einer reduzierten Bildung von 
Entzündungsmediatoren. Zusätzlich beschreiben wir einen Effekt von TNF-α Pre-
konditionierung auf die Effizienz des Caspase Unterdrückers Z-DEVD-FMK. Unsere 
Ergebnisse bringen Einsichten in den Überlebensmechanismus einer ischemisch 
herausgeforderten Zelle in der Situation des TNF-α vermittelten Zellschutztes. Dies 
könnte zu neuen Herangehensweisen im Kontext der Entzündungsbehandlung führen, 
durch Stoffe, die differnziell den zellulären cPLA2  Verkehr kontrollieren.  
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Motivation 
 
There is increasing evidence that inflammatory reactions in infarcted tissue have a 
major impact on the outcome of the infarction per se (Pasupathy and Homer-
Vanniasinkam, 2005). The consequences of those reactions, which are of local and 
systemic nature induce a positive feedback mechanism which worsens the injury over 
time (Mann, 1996). However, many tissues have the inherent capacity to increase 
their resistance to an ischaemic insult and to decrease the generation of inflammatory 
mediators. This phenomenon, where a short ischaemic period prior to a subsequent 
prolonged ischaemic event reduces the extent of infarction, was termed ischaemic 
preconditioning (IPC). When this powerful anti-infarct effect was discovered in 1986 
(Murry et al., 1986), great hope arose for the development of effective treatment for 
cardiac illness. However, despite advances in the prevention and treatment of heart 
disease, cardiac illness still represents a growing threat to our society (Bradshaw, 
2005). Not only is there no satisfactory means to treat heart disease but heart failure is 
also a progressive disease, continuously reducing the patient’s quality of life.  
 
The cytokine tumour necrosis factor alpha (TNF-α) has been the centre of attention in 
this context. Its effects vary according to the dose: at low doses it has been shown to 
mimic the effect of preconditioning (Lecour et al., 2002), whereas higher doses have a 
negative effect on heart function, with the levels of TNF-α in the heart being 
proportional to the degree of heart failure (Seta et al., 1996). However, very recent 
clinical trials with the aim of reducing this cytokine concentration in heart failure 
patients, had to be stopped due to the disappointing outcome. These findings call for 
more in-depth understanding with regard to the signalling mechanisms involved 
(Mann, 2005). One important role player influencing inflammation in infarcted tissue 
is the inflammatory mediator generating enzyme cytosolic phospholipase A2 (cPLA2), 
which, since it is calcium dependent, takes a special place within the ischaemic 
context. We therefore became interested in the role of cPLA2 in the cytoprotective 
effect associated with low dose TNF-α. We hypothesize a role for cPLA2 in TNF-α 
mediated cytoprotection, possibly on the level of cPLA2 activation and 
phosphorylation, or through a specific cPLA2 translocation. This motivated us for the 
conduction of this study.  
 xxv
We hope that our results widen our ideas and indicate new doors for the development 
of pharmacological agents which can bring about an effective anti-infarct therapy and 
enable us to optimize our knowledge applied in clinical trials.  
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Chapter 1: Literature Review 
 
1. Preconditioning  
 
1.1. Concept and context of ischaemic preconditioning  
 
1.1.1. Introduction  
 
In 1986 a powerful anti-infarct effect was discovered. It was found that exposure of 
the myocardium to a brief episode of sub-lethal ischaemia and reperfusion markedly 
reduced tissue necrosis induced by subsequent prolonged ischaemia (Murry et al., 
1986). This phenomenon was termed ischaemic preconditioning (IPC).  
 
The term ischaemia describes “the hindrance of blood supply and the increase in the 
resistance of flux” and is derived from the Greek “ischein”, to restrict and “haima”, 
meaning blood. The term clinical ischaemia has since been refined to mean “a relative 
shortage of blood supply in the coronary circulation, which induces a shortage in the 
supply of oxygen and substrate and leads to the accumulation of metabolites”. This 
condition of ischaemia can be mimicked in an experimental setup and is termed 
simulated or experimental ischaemia. It involves aerobic/anaerobic metabolic 
inhibition of tissue as well as a low pH, a high potassium concentration and hypoxia. 
The term index ischaemia is used to describe the prolonged ischaemic event.  
 
Twenty years after the discovery of IPC, this endogenous myocardial protection is 
still a field of intense research. Despite advances in the prevention and treatment of 
heart disease, cardiac illness ranks as the most frequent cause of mortality. In the 
United States it has reached epidemic proportions (Cohen et al., 2000). The South 
African National Burden of Disease study for the year 2000 estimated that 17% of all 
deaths were due to cardiovascular diseases, where ischaemic heart disease accounted 
for 35% of cardiovascular deaths (Bradshaw, 2005). According to the World Health 
Organization cardiac illness will be the major cause of death in the world as a whole 
by the year 2020 (Murray and Lopez, 1997).   
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1.1.2. Reperfusion injury 
 
Prolonged occlusion of a coronary artery can have deadly effects on the myocardium 
it supplies. Because infarct tissue is no longer able to contract, the global function of 
the heart can be severely impaired. Restoration of the circulation brings about 
reperfusion of the cardiac tissue and is essential for the re-establishment of oxidative 
phosphorylation and removal of accumulated waste products. However, reperfusion 
induces tissue damage, termed reperfusion injury. This injury has two serious 
consequences, of local and of systemic nature. Whilst ischaemic injury is mainly 
caused by tissue oxygen-deprivation and cellular necrosis, reperfusion injury produces 
an inflammatory response. This inflammatory response feeds back into the local 
damage, worsens it over time and leads to a systemic insult (Pasupathy and Homer-
Vanniasinkam, 2005).  
 
1.1.3. IPC and the current problem of rescuing the myocardium  
 
Although the concept of IPC describes one of the most powerful methods of 
minimising ischaemia/reperfusion (IR) injury, currently the only proven way of 
rescuing the ischaemic myocardium is urgent revascularization of the involved 
coronary artery, with the aim of minimizing both ischaemic and reperfusion injury. 
This can be achieved with pharmacological agents to lyse the occluding thrombus, 
with catheter-based interventions and angioplasty, with stenting or atherectomy. 
These techniques are all intended to either mechanically displace or remove the 
occluding atherosclerotic plaque.  Alternatively, surgical bypass procedures may be 
used, to re-route arterial blood around the obstruction (Cohen et al., 2000). However, 
even if these sophisticated methods are available, the period between patient 
presentation and successful revascularization is often too long to avoid considerable 
infarction and reperfusion injury. This time period is crucial since the extent of tissue 
necrosis is proportional to the duration of the time interval between coronary 
occlusion and re-established flow (Cohen et al., 2000). It is therefore desirable to 
make the tissue less susceptible to ischaemic and reperfusion injury and to develop a 
means of protecting the heart from infarction before revascularization takes place.  
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IPC has the potential to play a main role in fulfilling these goals. So far our 
knowledge certainly underlines the complexity of IPC. It has been argued that we 
know enough to translate accumulated data into effective clinical application (Opie, 
1997). On the other hand, disappointing clinical trials especially regarding 
inflammatory role players demand more in-depth knowledge. It is hoped that 
elucidation of the mechanism for IPC will yield therapeutic strategies capable of not 
only reducing the severity of myocardial infarction but also reducing the 
inflammatory response, which is induced following cardiac tissue necrosis. Therefore 
the centre of attention is the pathway or pathways used for IPC and the manipulation 
of the signalling events defining the pathway, which can lead to the development of 
effective anti-infarct therapy.  
 
1.2. Ischaemic Preconditioning 
 
1.2.1. Infarct size limitation is possible in many species, including humans 
 
The report of a delay in lethal cell injury in myocardium due to ischaemic 
preconditioning put the scientific community on alert.  For the first time it was shown 
that infarct size limitation was possible. It was demonstrated that four 5 min brief 
cycles of I/R via occlusion of the coronary artery provided robust myocardial 
protection from a further prolonged 40 min ischaemic insult in the canine heart. The 
zone of infarcted myocardium from these hearts was reduced by 70% compared to 
control hearts at 4 days post-reperfusion (Murry et al., 1986). Similar and 
reproducible results were observed in other species including rats (Mitchell et al., 
1995), rabbits (Cohen et al., 1991), chicken, mouse, sheep and pig (Liang and Gross, 
1999). For ethical reasons it has not been possible to test directly whether 
preconditioning can protect human hearts against infarction, but evidence speaks for 
it.  It has been demonstrated that recovery of function in isolated human atrial 
trabeculae, after an extended period of hypoxia, was greatly enhanced by earlier 
hypoxic preconditioning. Furthermore, preconditioning has been shown to protect 
human ventricular myocytes against simulated ischaemia in vitro (Cohen et al., 2000). 
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1.2.2. Time frames and dose response dynamics of IPC 
 
Two different time frames are defined for IPC, one described as early or classical 
preconditioning and one as late, delayed or the so called second window of 
preconditioning (SWOP) (Kuzuya et al., 1993). Early preconditioning provides 
protection for about 2-3 hrs, whilst SWOP remains protective for 48-96 hrs (Bolli, 
2000) (Figure.1.1.). The magnitude of protection differs however, as well as the 
mechanism leading to protection (Pasupathy and Homer-Vanniasinkam, 2005). It is 
thought that immediate protection is due to the activation of membrane receptors and 
post-translation events, whilst delayed protection more likely involves gene 
expression and protein synthesis, such as  the overexpression of heat shock proteins 
(Perrault and Menasche, 1997; Bolli, 2000). Regarding the dose response dynamics of 
IPC, conflicting information is available. On the one hand it has been proposed, that it 
is highly likely that repeated preconditioning episodes are neither additive nor 
cumulative (Pasupathy and Homer-Vanniasinkam, 2005). However, it has been shown 
that there is a difference in the degree of protection depending on single-or multi-
cycle ischaemia (Sandhu et al., 1997). A very steep dose-response curve for IPC has 
been described (Pasupathy and Homer-Vanniasinkam, 2005). Once a maximal 
response is achieved, further stimulation has no additional effect (Pasupathy and 
Homer-Vanniasinkam, 2005). It is further of note that preconditioning´s protection is 
lost when the ischaemic insult is extended to 3 hrs, indicating that reperfusion after a 
lethal ischaemic insult is an absolute necessity for protection (Yellon and Downey, 
2003). The duration of the reperfusion period after the preconditioning stimulus has to 
be at least 30-60 seconds, in order to provide protection (Alkhulaifi et al., 1993). IPC-
induced protection is manifested through delaying cellular death rather than 
preventing it. A time delay reducing the actual duration of the ischaemic insult by 20 
to 30 min has been suggested (Yellon and Downey, 2003). Therefore, preconditioning 
increases the tissue’s capacity for tolerating an ischaemic insult and thereby buys out 
lethal time for the benefit of tissue survival.  
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Figure 1.1. Biphasic protection induced by a preconditioning episode 
(modified from Pasupathy and Homer-Vanniasinkam, 2005). 
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1.2.3. Physiological Mechanisms of I/R tolerance 
 
The following physiological mechanisms by which ischaemic preconditioning induces 
ischaemia tolerance, have been suggested (Pasupathy and Homer-Vanniasinkam, 
2005).  
 
 Ionic equilibrium during prolonged ischaemia is maintained   
 Cellular energy demand is reduced   
 Cellular ATP consumption is reduced 
 Rate of glycolysis is reduced 
 Intra-cellular energy relays become more efficient 
 H+ production is decreased due to a better maintained ionic household linked 
to the less affected Na/K ATPase 
 
Many of these mechanisms in the ischaemic phase are directly or indirectly related to 
the cellular energy household (Hearse, 1994). On the other hand, the parameters 
whereby preconditioning induces reperfusion tolerance, are centred around a better 
maintained intracellular redox potential, a reduced production of free oxygen radicals, 
a reduction in the release of cytokines as well as the preservation of mitochondrial 
integrity (Pasupathy and Homer-Vanniasinkam, 2005). 
 
1.3. Cellular Mechanisms of IPC and Pharmacological Preconditioning 
 
Most of the insight into the pathway mechanisms of IPC has been established in 
cardiac muscle tissue compared with skeletal muscle tissue. It has been shown that 
IPC is indeed a phenomenon of the myocardial cell (Piper and Ladilov, 1997) and an 
immense body of knowledge regarding the signalling pathways has been established 
through using cardiomyocytes isolated from the adult or neonatal rat heart. The 
isolated cell model has shown that when submitting cardiomyocytes to a 
pharmacological preconditioning protocol through protein kinase C (PKC) 
stimulation, the cell is protected against Ca2+ overload in the ischaemic event. 
Therefore preconditioning could be thought of as a lessening of calcium-mediated 
damage (Opie, 1997). Under reoxygenation conditions, cardiomyocytes have been 
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shown to be protected against the occurrence of reoxygenation induced 
hypercontracture (Piper and Ladilov, 1997). How the tissue remembers, 
mechanistically, that it has been preconditioned, seems to remain a mystery. Gene 
expression can most likely be eliminated since when protein synthesis is inhibited, the 
early preconditioning´s protection cannot be blocked  (Thornton et al., 1990). 
Furthermore, a preconditioned state can be achieved within 10 min, leaving an 
unrealistic time window for protein expression. However, reversible posttranslational 
protein modifications, such as phosphorylation, dephosphorylation and translocation 
seem much more likely events that bring about the cellular response to IPC.    
 
1.3.1. The Preconditioning pathway - an interplay in series 
 
The mechanism of IPC is emerging as a complex interplay of receptors, protein 
kinases, and ion channels in series (Cohen et al., 2000). Locally released agonists, 
such as adenosine, bradykinin, catecholamines and opioids trigger the protection via 
cell surface G-protein coupled receptors (Pasupathy and Homer-Vanniasinkam, 
2005). Therefore, IPC is a receptor mediated phenomenon with a highly redundant 
receptor system. Kinases like PKC, protein tyrosine kinase (PTK) and p38 mitogen 
activated protein kinases (MAPK) participate in the signalling pathway. The end-
effector remains elusive, although the mitochondrial ATP-sensitive potassium (KATP) 
channel might likely serve this role, preventing the opening of the mitochondrial 
permeability transition pore (Cohen et al., 2000), (Yellon and Downey, 2003) 
(Pasupathy and Homer-Vanniasinkam, 2005) (Figure 1.2.). Many studies indicate that 
drugs can imitate or prevent IPC. Due to the cascade-like fashion of the pathway, 
there are multiple points offering intervention, which is practically appealing when 
duplicating the protective action of ischaemically induced preconditioning. Within the 
signalling pathway of IPC, three levels of molecular targets can be considered: 
triggers, mediators and effectors (Perrault and Menasche, 1997). Triggers act before 
simulated ischaemia whilst mediators act during the simulated ischaemic event. This 
classification however should be seen as a guiding framework only. Although 
literature often refers to these terms, their application demands caution, since borders 
often overlap resulting in grey areas.  
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Figure 1.2. A simplified schematic representation of a proposed mechanism of IPC is 
shown. Ischaemia leads to the release of adenosine, bradykinin and opioids that can 
activate phospholipase C (PLC); PLC can lead to the translocation and activation of 
protein kinase C (PKC) which can initiate a complex kinase cascade involving 
mitogen activated protein kinases (MAPKs). This can lead to the opening of 
mitochondrial KATP channels. However, many steps within this sequence remain 
unknown (modified from Cohen et al., 2000). 
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1.4. Skeletal Muscle Preconditioning 
 
Several investigators have shown that ischaemic preconditioning also serves to protect 
skeletal muscle tissue from subsequent ischaemic damage. It is likely that molecular 
mechanisms of preconditioning in skeletal muscle are virtually identical to those in 
myocardial tissue (Kohin et al., 2001). This has been demonstrated in the whole 
organ, tissue and cellular level (Pang et al., 1997). Most work in the field has been 
done by Pang and colleagues, working with porcine skeletal muscle. He and his group 
speculated for the first time that there is potential clinical application of the ischaemic 
preconditioning phenomenon for skeletal muscle against infarction if the protective 
effect can be induced in the same way as in cardiac muscle (Pang et al., 1995). They 
observed a 44% and a 62% decrease in the extent of muscle infarction in latissimus 
dorsi and gracilis muscle flaps respectively, when these muscles were subjected to 4 
hrs of ischaemia and 48 hrs of reperfusion. Furthermore, preconditioning was 
associated with higher muscle content of high energy phosphates and less muscle 
accumulation of lactate during sustained ischaemia compared with the control muscle 
flaps (Pang et al., 1995).  Subsequently more effort was spent on determining the 
optimal ischaemic time and number of cycles, to apply IPC most effectively (Saita et 
al., 2002). It was shown that three to five cycles of 10 min preconditioning achieved a 
superior protective effect compared with one or two cycles (Saita et al., 2002). 
Preconditioning of single skeletal muscle fibres also improved function and recovery 
during severe hypoxia and reoxygenation. In this experimental setting, hypoxia alone 
was used to ischaemically challenge the cells, without modulating the cellular 
environment in terms of pH, buffer and metabolic inhibition. An improved force 
production and attenuation of changes in Ca2+ handling was observed (Kohin et al., 
2001). Homer and colleagues have demonstrated in a rodent hindlimb model after 6 
hrs of ischaemia and 4 hrs of reperfusion, that muscle blood flow during the 
revascularisation period was reflected in a triphasic pattern, low reflow at 10 min of 
reperfusion, improving at 120 min, and significantly diminished blood flow at 240 
min of reperfusion, representing the reperfusion injury (Homer-Vanniasinkam et al., 
2001).  
 
In skeletal muscle, the deleterious effects of I/R appear to be closely associated with 
proinflammatory processes. There is experimental evidence indicating the possibility 
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that preconditioning may reduce platelet aggregation and neutrophil adherence in 
ischaemic skeletal muscle (Pang et al., 1995). Increased intracellular Ca2+ during I/R 
seems to be a primary cause of post ischaemic injury in muscle cells. Ca2+ 
homeostasis may initially be disrupted through reactive oxygen species (ROS) 
induced injuries and subsequent disturbances in Ca2+ handling may follow. 
Furthermore, elevations in intracellular Ca2+ activate proteases and phospholipases 
that can cause irreversible cellular and mitochondrial damage (Kohin et al., 2001).   
 
1.5. IPC in other tissues 
 
Preconditioning was first described in the heart, but since then it has been described in 
various organs such as the gut (Ishida et al., 1997) kidney (Bonventre, 2002) and skin 
(Rosken et al., 1998). Preconditioning in the brain is only protective in the second 
time window (Kirino, 2002), demonstrating a degree of tissue specificity. However, 
preconditioning in skeletal muscle seems to be most similar to the preconditioning 
events found in cardiac tissue (Kohin et al., 2001).  
 
1.6. Clinical Relevance of Preconditioning  
 
There is convincing evidence indicating that ischaemic preconditioning can and will 
occur in humans. Patients may have experienced numerous angina attacks before 
suffering from myocardial infarction and some of these episodes may have 
preconditioned the myocardium. The therapeutic exploitation of these natural adaptive 
mechanisms in cardiac surgery is intellectually an appealing prospect (Perrault and 
Menasche, 1997) and has led to successful clinical application of IPC to coronary 
angioplasty and coronary bypass grafting (Pasupathy and Homer-Vanniasinkam, 
2005). Recent clinical trials in pulmonary and hepatic surgery also involve IPC 
application (Pasupathy and Homer-Vanniasinkam, 2005). However, clinical progress 
is very slow. It has been argued that enough knowledge about IPC is available to plan 
appropriate pharmacological responses (Opie, 1997), and that more experiments 
would only contribute to more confusion rather than clarification. Others (de Jong and 
de Jonge, 1997) are convinced that as long as the end effector is elusive, more 
pharmacological experiments are needed. When looking especially at the differences 
between low-flow and no-flow induced ischaemic injury, concern has been raised 
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regarding and suggestions been given, that additional work is needed (de Jong and de 
Jonge, 1997). Most preconditioning experiments focus on no-flow ischaemic injury 
after the pre-treatment, however, in the clinical practice low-flow conditions are more 
likely to occur, due to partial coronary occlusion or collateral flow (de Jong and de 
Jonge, 1997). The concern addresses differences in receptor binding dynamics due to 
wash out and agonist availability. Furthermore metabolic and ionic differences are 
apparent when comparing no-flow and low-flow induced ischaemic injury (El Banani 
et al., 2000).    
 
Unfortunately, in the case of skeletal muscle preconditioning, clinical progress is also 
slow. In many clinical conditions, single or multiple skeletal muscle fibres are 
subjected to global ischaemia and would benefit from IPC. This would be the case 
during muscle transplantation or surgical muscle reconstruction. The tolerance of 
skeletal muscle to global ischemia is comparatively large, but only up to a point. 
When this tolerance is exceeded in excessive ischaemia, I/R injury and muscle 
necrosis can result. A massive infarction may induce life threatening acidosis and 
hyperkalaemia. Skeletal muscle reperfusion injury is characterized not only by 
necrosis but also impaired muscle contraction, endothelial cell swelling, release of 
intracellular enzymes and proteins and increased microvascular permeability to 
proteins (Homer-Vanniasinkam et al., 2001). In diabetic and nondiabetic patients with 
disturbed haemodynamic parameters such as in lower limb arterial disease, defined by 
recurring ischaemic rest pain, IPC might be an additional treatment strategy for 
optimal medical care (Vayssariat et al., 1997). Following surgery for acute limb 
ischaemia, a major amputation may be required in up to 15% of cases despite a 
technically successful operation (Homer-Vanniasinkam et al., 2001). 
 
In summary, knowledge and understanding of the mechanism employed in IPC 
demands translation to the bedside. It seems that the application of what we do know 
is overridden by the wish to increase our understanding of existing data and the fear 
of inducing side effects such as arrhythmias when for example intervening with 
cardiac ATP-sensitive K+ channel modulating drugs (Opie, 1997).  
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 2. TNF-α  
 
2.1. TNF-α - the proinflammatory cytokine in myocardial homeostasis 
 
The functional role of Tumor necrosis factor-alpha (TNF-α) in the myocardium and 
other tissues has been studied extensively over the past several years. However the 
partly beneficial as well as potentially adverse effects of TNF-α in the cardiovascular 
setting are only marginally understood. With the “cytokine hypothesis” 10 years ago, 
it was recognized that the pro-inflammatory cytokine, TNF-α, is involved in virtually 
all forms of cardiac injury. This paradigm shift away from a primarily haemodynamic 
disorder and towards biologically active molecules such as cytokines has since been 
substantiated. The term cytokine describes a group of small molecular weight proteins 
(15-30 kDa), that are secreted by a broad variety of cells in response to different 
inducing stimuli. In response to cellular environmental stress, they act primarily in a 
juxtacrine, paracrine and autocrine fashion; however when produced in large amounts, 
they also can exert endocrine effects.  
 
Two major classes of cytokines have been identified, vasoconstrictor cytokines such 
as endothelin and “proinflammatory” cytokines such as TNF-α (Seta et al., 1996). 
Despite recruiting and stimulating cellular components of the immune system, 
proinflammatory cytokines induce their own production as well as the synthesis of 
small inflammatory mediators such as platelet-activating factor (PAF) and oxidative 
radicals (Meldrum, 1998). TNF-α was originally discovered as a necrosis-inducing 
protein in certain mouse tumours. Now it is recognized as a cytokine with pleiotropic 
capacities, including effects on growth, differentiation and apoptosis in virtually every 
cell type investigated, including cardiac myocytes and skeletal muscle myotubes (Li 
and Schwartz, 2001). The pleiotropic effect of TNF-α is facilitated via the activation 
of caspases, mitogen activated protein kinases (MAPKs), transcription factors, 
activated protein-1 (AP-1) and nuclear factor-kB (NF-kB). In this way TNF-α 
mediates pro-apoptotic and pro-survival mechanisms in the cell. It has been suggested 
that TNF-α adjusts the redox potential of the cell through reactive oxygen 
intermediates, which mediate parts of the decision making of the cell between 
survival or apoptotic death (Garg and Aggarwal, 2002). Furthermore, it is part of a 
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network that orchestrates inflammatory events. TNF-α and TNF-β share similar 
inflammatory activities; however, TNF-β, or as it was first described, “Lymphotoxin” 
is less potent and mainly produced by T-cells, whereas macrophages are the 
predominant generators of TNF-α.  
 
Confirmed in numerous experimental materials, it has been shown that TNF-α plays 
an important role in mediating and integrating the myocardial response to stress 
(Mann, 1996). It plays a crucial role in maintaining myocardial homeostasis via the 
integration of cytoprotective-, hypertrophic- or repair-orientated responses (Mann, 
2003). According to the cytokine hypothesis, heart failure is induced because cytokine 
cascades intensify haemodynamic abnormalities or exert direct toxic effects on the 
tissue (Seta et al., 1996).  
 
2.2. TNF-α synthesis and control  
 
The various control mechanisms from gene induction to post-release buffering 
underpin the potency of TNF-α. Although TNF-α generation was initially described as 
a lipopolisaccharide (LPS) induced macrophage product, it has now been shown that 
cardiac myocytes themselves are capable of substantial TNF-α synthesis, when 
stimulated appropriately (Meldrum, 1998). In fact, the myocardium is capable of 
generating amounts of TNF-α equal to those in the liver or spleen, organs with large 
macrophage populations (Meldrum, 1998).  After an ischaemic event, TNF-α 
accumulation can be visualised immunohistochemically within the cardiomyocytes, 
while before ischaemia, only cardiac residential macrophages show a TNF-α signal.  
TNF-α gene expression is tightly regulated and baseline levels are rapidly restored 
after the stress stimulus has ceased. Nuclear factor kappa B (NFκB), a redox-sensitive 
transcription factor, regulates a battery of inflammatory genes, amongst them the 
TNF-α gene (Valen et al., 2001). Once NFκB is liberated from the inhibitory protein 
IκB, it translocates from the cytoplasm to the nucleus, where it docks to one of four 
TNF-α promoter sites. Once the TNF-α gene has been transcribed, TNF mRNA is 
translated into a 26-kDa TNF precursor or a 233 amino acid pro-hormone. A 
transcriptional control-, as well as post transcriptional stabilisation mechanism of 
TNF-α mRNA has been suggested to govern TNF-α availability (Mann, 1996). 
Because TNF-α contains a 33 nucleotide 3´-untranslated sequence that shortens 
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messenger RNA half life, the production of large quantities of this potent peptide is 
inhibited (Feldman et al., 2000). The mature 17-kDa and 157 residue TNF-α is 
released into the extracellular space after cleavage by a TNF-α converting enzyme 
(TACE) (Feldman et al., 2000). TNF-α mRNA is not detectable in naive hearts, but is 
expressed de novo within 30 minutes following a stressful event (Mann, 1996). The 
same pattern is followed for biologically active TNF-α protein.  In the presence of 
noxious stimulants including TNF-α and LPS, TNF-α receptors are “shed” into the 
circulation as truncated fragments of the extracellular regions (Feldman et al., 2000). 
This mechanism serves as an additional post-release control to biologically “buffer” 
TNF-α activity.  
 
Due to the extensive study of macrophages, the intracellular signalling pathways that 
provoke TNF-α production have been elucidated. Lipopolysaccharides (LPS) or 
ischaemia/reperfusion activate myocardial p38 MAPK and NFκB, which leads to 
TNF-α production. Binding of LPS binding protein (LBP) to CD 14 surface receptors 
triggers TNF-α production (Meldrum, 1998). This protein receptor interaction also 
causes rapid activation of protein tyrosine kinase, which in turn induces 
phosphorylation of intracellular protein kinases such as MAP kinase kinase. Ras is an 
early target of activated PTK and interacts directly with Raf-1. Raf-1 is an important 
intermediate to MAPK activation. The p38 MAPK appears to be a pivotal MAPK in 
the cascade leading to TNF-α gene induction (Meldrum, 1998).  
 
2.3. TNF-α pathways 
 
2.3.1. TNF-α receptors and downstream pathways 
 
The Kd of TNF-α for its receptor was found to be in the range of 0,3 to 1 nM, 
indicating the TNF-α level required for eliciting a physiological effect (McVey et al., 
1999). Biological effects of TNF-α are induced by binding to two distinct cell surface 
receptors, known as TNFR1 and TNFR2, with a molecular weight of 55 kDa and 75 
kDa respectively. They signal as homotrimers and can exist either membrane-bound 
or as a truncated soluble form (Sack, 2002). The presence of both receptors in the 
heart has been described and their location has been immunolocalized. Although they 
share homology in their extracellular domains, the intracellular parts are different and 
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suggest distinct modi for signalling and cellular function. Signalling pathways 
coupled to the high affinity TNFR1 are known in more detail and include the 
activation of phospholipase A2, phospatidylcholine specific phospholipase C and 
activation of neutral and acidic sphingomyelinases. TNF-α induces sphingosine 
mediated apoptosis via TNFR 1 and its “death domain”, whilst NFκB is induced via 
TNFR2. TNFR1 and Fas receptors are linked to cytoplasmic proteins, called TRADD 
and FADD, TNF receptor associated death domain and Fas-associated death domain 
respectively (Meldrum, 1998).  Communication between these death domain proteins 
is achieved by receptor-interacting protein (RIP) that facilitates the signal and leads 
via endonuclease activation to nuclear DNA fragmentation. TNFR2 communicates 
with TNF receptor associated factors (TRAFs). TRAFs contain zinc finger motifs that 
enable them to modulate transcription factor activity. To make things more complex, 
TNFR1 and TNFR2 pathways can cross activate each other and thereby channel the 
pathway flux (Figure 1.3.).  
 
2.3.2. TNF-α induced apoptosis 
 
Programmed cell death (apoptosis) is a process by which the cell undergoes inducible, 
ATP dependent, non necrotic cellular suicide. The death domain activation with its 
subsequent activation of TRADD and FADD and caspase-8, leads to caspase-3 
activation and ultimately apoptosis (Garg and Aggarwal, 2002). However, a second 
pathway mediated via the mitochondria, can be recruited. Reports show that 
mitochondria are the major source of reactive oxygen intermediates that mediate 
TNF-α induced signalling (Garg and Aggarwal, 2002). TNF-α alters the 
mitochondrial membrane permeability, cytochrome c release and subsequent caspase 
activation, which can lead to apoptosis. Cardiac myocyte apoptosis occurs amongst 
others in ischaemia and chronic heart failure. The decision making between necrotic 
and apoptotic cell death is an important process, since it determines the overall 
organism response dramatically. Apoptosis is characterized by the maintenance of cell 
membrane integrity, therefore the release of inflammatory mediators such as TNF-α is 
prevented and a systemic immune response cannot take place. Despite these systemic 
versus locally controlled consequences, one finds functional implications in this 
context. For example, apoptotic myocytes, in contrast with their necrotic partners,  
 
 16
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Schematic representation of TNF-α, its cell surface receptors and 
associated signalling molecules. Details are discussed throughout the text. TNFR, 
TNF-α receptor; TRADD, TNFR-associated protein with death domain; TRAF, 
TNFR-associated fctor; FADD, Fas-associated death domain; AP-1, activator protein-
1; RIP, receptor interacting protein; NFκB, nuclear factor κB (modified from Sack, 
2002). 
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maintain myofilament responsiveness to calcium ionophore, which dramatically 
determines the outcome of contractile performance (Meldrum, 1998). 
 
2.4. Dose and temporal dependent action pattern of TNF-α 
 
The TNF-α dose and temporal dependent pattern of action is well known and has 
withstood the test of time (Sack, 2002). It has been shown that the short term versus 
long term expression of TNF-α brings about a differential response. Short term 
expression may provide an adaptive response, whereas long-term expression induces 
maladaptation (Mann, 1996). In 1990 it was recognized for the first time, that 
circulating levels of TNF-α were elevated in patients with end stage heart failure and 
cachexia (Feldman et al., 2000). Elevated levels of TNF-α are detected peripherally 
following myocardial infarction as well as in unstable angina, myocardial reperfusion 
injury, hypertrophic cardiomyopathy and heart failure (Mann, 1996). TNF-α has also 
been recognized as a mediator responsible for the contractile dysfunction following 
coronary microembolization, a frequent complication of atherosclerotic plaque 
rupture (Dorge et al., 2002).  
 
2.4.1. TNF-α overexpression  
 
Cardiac specific overexpression of TNF-α in transgenic mice has shown that robust 
amounts of expression have a lethal outcome due to fulminant myocarditis. In 
transgenic mice where TNF-α expression levels allow the development of viable 
mice, they present with a similar pathologic, cellular and molecular phenotype to that 
seen in heart failure in humans, eg. chamber dilation, myocyte hypertrophy and 
matrix remodelling with fibrosis (Feldman et al., 2000). 
 
2.4.2. Maladaptive response 
 
Maladaptive responses due to a high dose TNF-α have been suggested to lead to left 
ventricular dysfunction, remodelling and cardiomyopathy as subsequent 
consequences. Direct injections of TNF-α produce hypotension, metabolic acidosis 
and death within minutes, mimicking the cardiac response seen during endotoxin 
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induced septic shock. Myocardial contractility is gradiently affected where an 
increasing TNF-α concentration leads to decreased myocardial contractility, an effect 
which is reversible upon removal of the cytokine (Mann, 1996). This is confirming 
the TNF-α induced production of immediate and delayed negative inotropic effects. 
Despite decreased contractility, haemodynamic effects of TNF-α are seen in a reduced 
ejection fraction, a decreased systemic vascular resistance and biventricular dilation 
(Meldrum, 1998).    
 
2.4.2.1. Mechanism of maladaptive responses 
 
Because calcium handling is crucial in facilitating contraction-relaxation, this field 
has been of special interest regarding maladaptation due to TNF-α. A decrease in the 
systolic amplitude of the calcium transient was observed after TNF-α application 
(Meldrum, 1998). This transition, a calcium induced calcium release from the 
sarcoplasmic reticulum ryanodine receptor is disturbed due to a disruption in the 
sarcolemmal voltage gated L-type calcium channel induced calcium influx (Meldrum, 
1998).  
 
The biphasic maladaptive response of the myocardium suggests two different 
mechanisms. Sphingosine and NO have been described as two players which can 
modulate the calcium transient (Meldrum, 1998). Sphingosine on the one hand might 
mediate the disrupted calcium release. It is rapidly produced and blocks the ryanodine 
receptor, thereby driving the calcium dyshomeostasis. Blockage of sphingosine 
production abolishes TNF-α induced contractile dysfunction. NO on the other hand 
mediates TNF-α induced desensitization of myofilaments to intracellular calcium 
(Meldrum, 1998). TNF-α is thought to increase the expression of the inducible nitric 
oxide synthase (iNOS). NOS inhibition could prevent the TNF-α induced myocardial 
depression (Meldrum, 1998). Also, a causally involved signal transduction cascade of 
NO, TNF-α and sphingosine has been described in coronary microembolization-
induced contractile dysfunction (Thielmann et al., 2002).  
 
Other contributors to the maladaptive response are direct TNF-α induced cytotoxicity, 
oxidant stress, myocyte apoptosis and the induction of other cardiac depressants such 
as interleukins (Meldrum, 1998). Furthermore, since TNF-α activates matrix 
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metalloproteinases (MMPs), changes in the balance between MMPs and tissue 
inhibitors of MMPs (TIMPs) activity are induced (Sarzi-Puttini et al., 2005). This 
could influence intercellular matrix composition, collagen turnover and flux of 
signalling molecules.  
 
2.4.3. Adaptive responses 
 
A growing body of evidence supports the notion that short term expression of pro-
inflammatory cytokines is beneficial. TNF-α has also been shown to up-regulate the 
expression of heat shock protein 72 (HSP 72), a protein thought to protect the heart 
against injury (Mann, 2003). It has been observed, that a concentration of < 10 U/ml 
TNF-α has no effect on HSP 72 expression, while a concentration of 50 U/ml 
produces significant increases. Although 1 unit (U) describes the amount of enzyme 
that catalyzes the reaction of 1 µM of substrate per minute, it is seen here as TNF-α 
activity. Pathophysiological TNF-α levels, such as 1000 U/ml result in less HSP 72 
levels compared to a 200 U/ml dose. Thus, short term TNF-α expression may provide 
additional homeostatic responses such as increased regional blood flow, increased 
resistance to ischaemia-induced arrhythmias through nitric oxide generation, 
increased free radical scavenging through increased expression of manganese 
superoxide dismutase and protection against hypoxic injury (Mann, 1996).   
 
2.4.3.1. Mechanism of adaptive responses and TNF-α preconditioning 
 
The expression of low concentrations of TNF-α for relatively short periods of time 
provides the heart with a short term adaptive response to stress. These patterns are 
mirrored when preconditioning the heart with a low dose of TNF-α for a short time 
period. Despite the capacity of  TNF-α to function as an ischaemic preconditioning  
mimetic, a dose dependent effect of TNF-α determined the outcome of tissue 
tolerance to ischaemia (Lecour et al., 2002) (Figure 1. 4.). Using recombinant TNF-α 
as preconditioning stimulus, a dose of 0.5 ng/ml TNF-α was most beneficial in 
myocardial infarct size reduction following the ischaemic event (Lecour et al., 2002). 
In this context, a role for sphingolipid second messengers in the TNF-α mediated 
preconditioning pathway has been suggested, since a ceramidase inhibitor could 
abolish the cardioprotective effect (Lecour et al., 2002). It has also been demonstrated 
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that IPC and TNF-α are interlinked via adenosine. It has been shown that adenosine´s 
anti-inflammatory effects include a decrease in cardiac TNF-α production following 
I/R injury, as well as the inhibition of neutrophil adhesion to cardiac myocytes 
(Meldrum, 1998). Ischaemic preconditioning or adenosine stimulation decreased 
myocardial TNF-α production and improved post-ischaemic functional recovery. 
These observations suggested a distal effector role of TNF-α production and amplified 
the attention drawn towards TNF-α as a role player within the preconditioning context 
(Meldrum et al., 1998). Cardioprotection by ischaemic preconditioning is associated 
with reduced TNF-α production during I/R (Belosjorow et al., 1999). When 
preconditioning is performed with TNF-α, it downregulates its own production. Using 
TNF-α null (TNF-α -/-) mice , it was shown that cardiac TNF-α production is a 
necessity for cardioprotection induced by IPC, substantiating a profound role of TNF-
α in the IPC cascade.  Furthermore, administration of a low dose  recombinant TNF-α 
mimicked IPC in wild-type mice, but not in the TNF-α deficient species (Smith et al., 
2002). Various upstream molecular signalling events, which influence TNF-α 
production, are present. Other forms of pharmacological preconditioning, such as 
treatment with calcitonin gene related peptide, are also capable of reducing cardiac 
TNF-α content (Peng et al., 2000).   
 
2.5. Effects of TNF-α preconditioning on skeletal muscle 
 
A growing body of knowledge has been established regarding the role of TNF-α in 
skeletal muscle; however more in the context of muscle degradation, myotube 
differentiation and only lately in TNF-α preconditioning. TNF-α has long been known 
to mediate skeletal muscle protein catabolism, therefore it was originally known as 
“cachectin”. It appears now, that TNF-α also serves a physiological role in skeletal 
muscle, since it is generated and up-regulated after strenuous exercise (Li and 
Schwartz, 2001).  It serves also as promoter in early phase myotube differentiation by 
stimulating NFκB and serum response factor (SRF) activity (Li and Schwartz, 2001). 
SRF is preferentially expressed in embryonic and adult cardiac and skeletal muscle 
tissue (Li and Schwartz, 2001).  Furthermore, it was shown that TNF-α can provoke a 
hypertrophic growth response by stimulating muscle proteins like α-actin and myosin 
heavy chain (MHC) (Li and Schwartz, 2001). Human derived Girardi cells and 
C2C12 myotubes were both shown to respond to ischaemic and pharmacological  
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Figure 1.4. The dose dependent cardioprotective effect of TNF-α in ng/ml. Shown is 
infarct size following 30 min coronary occlusion and 2 hrs of reperfusion. * p<0.01 vs 
conrol group (from Lecour et al., 2002).  
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preconditioning in a similar manner with the induction of mitochondrial uncoupling. 
This has drawn the attention to the importance of mitochondrial energetics within the 
preconditioning programme (Minners et al., 2001). The similarities of skeletal muscle 
characteristics, compared with cardiac muscle, has led to the application of skeletal 
muscle cell lines to serve as a model for cardiac research. 
 
2.6. Clinical relevance for anti TNF-α therapy and TNF-α tissue   
        preconditioning 
 
With TNF-α as role player in the clinical context the benefits could be two fold:  
1. to decrease TNF-α tissue concentration to decelerate heart failure progression and 
inflammation and  
2. to protect the heart from ischaemic injury. 
 
TNF-α might have prognostic significance in heart failure and as biochemical marker 
for the progression of left ventricular dysfunction. A progressive increase in 
peripheral TNF-α  levels has been described in direct relation to the patient’s New 
York Heart Association (NYHA) classification in comparison to age-matched control 
subjects (Figure 1.5.) (Seta et al., 1996). However, for reasons that are unclear, only 
about 30-40% of the patients with heart failure show this TNF-α elevation.  
 
Anti TNF-α strategies could prove to be beneficial in the treatment of patients with 
heart failure and a series of phase I clinical trials with moderate to advanced heart 
failure patients led to promising improvements, such as increased walking distance 
and ejection fraction (Sarzi-Puttini et al., 2005). Also in subjects with rheumatoid 
arthritis, treatment with the soluble TNF-α receptor peptide as well as the monoclonal 
antibody against TNF-α, infliximab, has been shown to reduce the symptoms 
accompanying the disease (Sack, 2002).  However, the results following multi-centre 
trials using the soluble TNF-α receptor peptide, etanercept, were very disappointing.  
In the study a relevant benefit of etanercept on the rate of death or hospitalization was 
ruled out (Mann et al., 2004). Reasons for the disappointing results might lie in a too 
drastic decrease of TNF-α level below the physiologically relevant levels. 
Complement fixation, pharmacodynamic interactions and genetic polymorphism as 
well as race or sex related implications might also have contributed (Sarzi-Puttini et 
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al., 2005). In fact, only recently a study demonstrated gender related differences in the 
preconditioning threshold as well as a variation in the expression of TNF-α (Pitcher et 
al 2005). If one compares this context with the difficulty of fine-controling blood 
sugar levels with insulin, one can imagine that this artificial “receptor shedding” is 
similarly far away from the fine-tuned and tight TNF-α control mechanisms occurring 
endogenously. A limited immune response such as a limit in the clearance of live 
bacteria might have been responsible for the mortality in clinical trials (Meldrum, 
1998). It has been shown that TNF-α knock out mice are unable to clear bacteraemia 
after Listeria monocytogenes infection. These mice develop normally but are highly 
susceptible to infections (Meldrum, 1998).  
 
Other ways to decrease cardiac the TNF-α level have to be identified. Inhibition of 
TNF-α transcription is not feasible, since it is needed in the heart. More distal 
inhibition, such as p38 MAPK or NFκB inhibition may have a greater appeal. In the 
mean time physicians are advised to exercise caution when using eternacept and not 
to use TNF- α blockers in patients with NYHA class III or IV (Mann et al., 2004).  
 
3. Cytosolic Phospholipase A2 (cPLA2) 
 
3.1. cPLA2 and inflammatory mediator synthesis 
 
Phospholipases A2 (PLA2) are ubiquitous enzymes that are present in most cells and 
tissues. Hydrolysis of cellular membranous phospholipids by PLA2s causes the 
release of free fatty acids and lysophospholipids. Many of the newly generated lipids 
have profound biological properties. They promote inflammatory reactions and 
participate in processes that lead to tissue injury. Four different PLA2 subfamilies can 
functionally be distinguished: a secretory PLA2 (sPLA2), a Ca2+ sensitive cytosolic 
PLA2 (cPLA2), a Ca2+-independent cytosolic PLA2 (iPLA2) and the PAF 
acetylhydrolases (PAF-Ahs). The 85 kDa Ca2+ sensitive cytosolic PLA2, also referred 
to as group IV cPLA2α, has been purified, cloned and biochemically characterized 
(Kramer and Sharp, 1997). Similar to TNF-α, cPLA2 was first characterized in 
macrophage cells. It is in fact the best characterized and most relevant isoenzyme for  
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Figure 1.5. TNF-α levels in patients with class I-IV heart failure, in comparison to 
age-matched control subjects. * p<0.05 vs control (modified from Seta et al., 1996). 
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intracellular signalling because it drives key activities in inflammatory mediator 
biosynthesis (Dessen, 2000). 
 
Group IV cPLA2α is the only PLA2 enzyme with marked preference for the second 
ester bond (sn-2) within the phospholipids molecule, cleaving AA over other fatty 
acids (Murakami et al., 2003). Arachidonic acid (AA) release is the rate limiting step 
in the biosynthesis of the potent mediators such as prostaglandins and leukotrienes. 
Therefore, cPLA2 supplies AA to the downstream cyclooxygenase (COX) and 
lipoxygenase (LOX) that catalyze the conversion of AA into prostaglandins, 
leukotrienes, thromboxanes and lipoxins (MacEwan, 1996). Interestingly, the 
cleavage of phospholipids appears in an order of preference for 
phosphatidylcholine>phosphatidylethanolamine>phosphatidylserine. The cellular AA 
levels are controlled by a fine-tuned deacylation-reacylation cycle of phospholipids. 
In cardiac cells, these processes are governed by lysophospholipid acyl transferase 
and PLA2. Liberation of AA may occur in a controlled manner, for example via 
ligand-receptor interactions, or in an uncontrolled fashion. Ischaemia/reperfusion 
mediates uncontrolled membrane phospholipid hydrolysis, causing significant 
elevation in AA levels with potential harmful consequences for cellular functioning 
(Van der Vusse et al., 1997). Additional members of cPLA2, namely cPLA2β and 
cPLA2γ have been cloned recently (Taketo and Sonoshita, 2002). cPLA2 is 
ubiquitously expressed in most adult human tissues with most prominent m-RNA 
levels in brain, heart and lung tissue (Hirabayashi and Shimizu, 2000).   
 
3.2. cPLA2 activation  
 
Two major avenues exist for cPLA2 activation. Firstly, it is the only known PLA2 that 
is functionally receptor-regulated and therefore takes part in receptor mediated 
intracellular signal transduction processes (Kramer and Sharp, 1997). Cytokines such 
as TNF-α can increase the activity of cPLA2 via phosphorylation and the induction of 
cPLA2 via the p70 TNFR. Secondly, the avenue via non-receptor mediated 
stimulation is mediated by physical and stressful stimuli such as oxidation, UV light, 
shear stress and hyperglycaemia. The intensity, duration and cooperative coincidence 
of the signals determine the immediate activation of cPLA2 (Hirabayashi and 
Shimizu, 2000). This activation is induced in the presence of 0,3 -2,0 µM Ca2+ in the 
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cytosol and it has been suggested that this Ca2+ increase, either derived from an 
increased influx or from increased mobilisation from intracellular stores,  is the 
predominant factor causing cPLA2 activation (Kramer and Sharp, 1997).  A 
hyperbolic response curve has been described displaying the relationship between 
enzyme activity and Ca2+ concentration (Tong et al., 1998). The Ca2+ signalling 
patterns can occur as single transients, repetitive oscillations or as a sustained plateau 
and can bring about differential translocation patterns (Hirabayashi and Shimizu, 
2000). With a transient [Ca2+] increase and rapid return to basal levels, the 
translocation is also transient with little AA release. A prolonged [Ca2+] increase over 
several minutes however, stabilizes the association of the enzyme and its target, 
resulting in abundant AA release. In this way the cell is able to discriminate between 
appropriate signals and to prevent “false” activation (Hirabayashi and Shimizu, 2000).   
 
In addition, cPLA2 activity can also be regulated via phosphorylation, resulting in 
enhanced catalytic activity. Four serine residues were found to serve as 
phosphorylation sites in human cPLA2, with Ser-505 and Ser-727 conserved in other 
species. The serine kinases, protein kinase C (PKC) and mitogen activated protein 
(MAP) kinases, are able to phosphorylate and activate cPLA2.  In that context it was 
shown that cPLA2 is a substrate for p42 as well as p38 MAP kinase via Ser-505 
phosphorylation (Figure 1.6).  Both MAP kinases capacitate in increasing the intrinsic 
enzymatic activity of cPLA2 (Kramer and Sharp, 1997). Phosphorylation via MAP 
kinases on the Ser-505 residue brings about a 2-3 fold increase in activity and it has 
been suggested that this phosphorylation could optimize substrate accessibility by 
modulating the inter-domain rotation angle (Dessen, 2000) as described below. 
Surprisingly however, p38 inhibition did not affect cPLA2 rapid mobilization (Kramer 
and Sharp, 1997). For maximal activation of cPLA2, phosphorylation has to precede 
the calcium induced translocation to membranes (Bunt et al., 1997). Importantly, in 
the absence of an increase in cytosolic Ca2+, phosphorylated cPLA2 fails to induce AA 
release, since Ca2+ is a necessity for cPLA2 binding to the membrane substrate.   
 
Extracellular stimuli can alter the levels of cPLA2 mRNA and protein levels. TNF-α 
as well as IL-1 and interferon-γ have shown to induce cPLA2 activation and synthesis 
in diverse cell models (Hirabayashi and Shimizu, 2000). There is also evidence for 
post transcriptional cPLA2 regulation, since multiple AUUUA sequences in the 3´ 
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region seem to govern mRNA stability (Hirabayashi and Shimizu, 2000). The cPLA2 
gene locus also contains the functionally related prostaglandin synthase 2 gene, which 
would make a coordinated regulation of related enzymes possible (Kramer and Sharp, 
1997). In addition, there are consensus sites amongst others for NFκB. The cPLA2 
cDNA encodes a 749 amino acid protein with a predicted molecular mass of 85.2 
kDa. It is of note that the sequence of murine cPLA2 is more than 95% homologous to 
the human sequence.  
 
3.3. cPLA2 structure, sub-cellular localization and translocation 
 
cPLA2 preferentially cleaves substrates presented at a membrane interface rather than 
in monomeric form (Dessen et al., 1999). Analysis of the subcellular distribution of 
cPLA2 in resting and stimulated cells indicated cPLA2 redistribution from the 
cytosolic to the membrane fraction upon stimulation. In a variety of cells, a 
translocation to nuclear and endoplasmic reticulum membranes has been observed, 
which seems to be cell- and stimulus specific (Kramer and Sharp, 1997). Co-
localization studies showed that when endothelial cells are stimulated with a calcium 
mobilizing agonist, a relocation of cPLA2 was highly specific, primarily to 
intracellular structures resembling the endoplasmic reticulum and Golgi apparatus as 
well as to the inner and outer surfaces of the nuclear membrane (Grewal et al., 2005). 
There is evidence that enzymes such as prostaglandin synthase I and II are localized 
in these regions, making the translocation locus an ideal position to provide optimal 
free arachidonic acid supply to the enzymes of the eicosanoid cascade, whose 
products in turn are subsequently available for intracellular recognition sites (Kramer 
and Sharp, 1997) (Figure 1.7.). In unstimulated cells a punctuate cytosolic labelling 
pattern has been observed by electron microscopy: no specific organellar membrane 
was preferred. This observation, that cPLA2 is localized in clusters, may have 
important implications for regulation and function (Bunt et al., 1997). The cPLA2 
molecule is composed of an N-terminal C2 domain with 138 amino acids and a 
catalytic unit with 611 amino acids. The C2 domain is responsible for the Ca2+ 
dependent binding of cPLA2 to membranes or phospholipid structures.The Ca2+ 
dependent phospholipid binding domain is essential for the translocation process 
(Bunt et al., 1997). Even a differential translocation of cPLA2 as a function of [Ca2+]  
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Figure 1.6. Schematic presentation of the activation mechanism of cPLA2. 
Phosphorylation of Serine505 leads to catalytic activity of cPLA2. Ca2+ (   ) , either 
released from endoplasmic reticulum (ER) or fluxed in during ischaemia due to Ca2+ 
homeostasis perturbations,  binds to the N-terminal calcium-dependent-phospholipid-
binding domain (CaLB) and promotes translocation to membranes (adapted from 
Hirabayashi and Shimizu, 2000). 
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amplitude and duration has been described, suggesting that the C2 domain regulates 
differential Ca2+ dependent membrane targeting (Evans et al., 2001).  
 
The C2 domain of cPLA2 binds Ca2+ ions, spaced 4 Å, without inducing major 
conformational changes in the protein structure upon Ca2+ binding (Hirabayashi and 
Shimizu, 2000). The domain consists of an 8 stranded antiparallel ß - sandwich, which 
can coordinate between one and three Ca2+ atoms through a constellation of acidic 
residues on three Ca2+ binding loops. The function of the C2 domain is to present the 
catalytic unit to the substrate in a productive fashion (Dessen, 2000). Essential amino 
acid residues important for the catalytic mechanism of cPLA2 are the Gly-Leu-
Ser228-Gly-Ser segment, with the central Serine228 as active site (Kramer and Sharp, 
1997). The cPLA2 structure reveals a flexible lid or cap that must move to allow 
substrate access to the active site (Dessen et al., 1999). The amphiphatic nature of the 
lid in cPLA2 suggests that the enzyme can change from a soluble closed conformation 
to an open, more hydrophobic form stabilized by membrane binding (Dessen et al., 
1999). The highly basic, 180 residue cap, positions itself right between the active site, 
which is buried into the catalytic domain core, and the C2 domain, providing a surface 
patch for membrane contact (Dessen, 2000). In order for catalysis to occur, the 
substrate must travel from the bilayer into the depths of the active site, which can only 
happen if the hydrophobic rim of cPLA2 is partially embedded in the target membrane 
(Dessen, 2000). Upon bilayer recognition, the catalytic unit is already strategically 
placed for substrate contact. A flexible inter-domain linker between the catalytic and 
the C2 domain as well as the lack of major protein interactions between them suggests 
the capacity of small rotations to accomplish optimal substrate targeting and optimal 
membrane interactions (Dessen, 2000 Dessen 99). The membrane binding itself is 
largely driven by hydrophobic interactions. It has been shown that the extent of 
membrane binding correlates with the amount of AA release (Hirabayashi and 
Shimizu, 2000).  
 
3.4. cPLA2 in the myocardium, IR injury and inflammation  
 
PLA2 have long been implicated in the pathogenesis of ischaemia and reperfusion 
injury and have attracted considerable interest as a pharmacological target in view of 
their involvement in lipid signalling and inflammatory conditions. In general, there  
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Figure 1.7. Translocation of cPLA2 from cytosol to perinuclear membrane following 
Ca2+ mobilizing stimulus. Perinuclear enzyme profile cyclooxygenase I and II (COX I 
and COX II) assures proximity for inflammatory mediator synthesis. Vimentin 
filament acts as a functional adapter for cPLA2 (adapted from Murakami et al., 2000).  
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are several mechanisms for PLA2 mediated injury, and due to the specific release of 
AA, cPLA2 is of special interest regarding its inductive injury. The most remarkable 
evidence regarding the role of cPLA2 in inflammatory mediator synthesis was shown 
in a cPLA2 knock out model. cPLA2-/- knock out mice subjected to 75 min focal 
cerebral ischaemia demonstrated a 34% reduction in brain infarct volume as well as 
less brain oedema and fewer neurological deficits than wild type mice (Sapirstein and 
Bonventre, 2000).  
 
Global ischaemia and the high intracellular levels of free Ca2+ resulting from 
ischaemic membrane depolarisation and opening of Ca2+ channels are likely to trigger 
cPLA2 activation (Kramer and Sharp, 1997). Cellular impairments during ischaemia, 
such as the acidification of the cytosol, disturbed Ca2+ homeostasis and alterations in 
physicochemical properties of the cellular membranes make the phospholipid 
constituents more vulnerable to cPLA2 activity, and a vicious cycle starts. After only 
10-20 min of ischaemia, increases in the cPLA2 activity and protein levels have been 
shown (Saluja et al., 1999). If preconditioning can be described as a lessening in 
calcium-mediated damage, then cPLA2 should have its place within that pathway. 
Proinflammatory cytokines such as TNF-α produced during ischaemia induce 
activation and de novo synthesis of cPLA2 and thus potentiate the mobilisation of 
cPLA2. Therefore, they play a crucial role in the rapid and prolonged cellular 
responses occurring during inflammatory processes. Furthermore, the production and 
release of reactive oxygen species produced in ischaemia and reperfusion induce 
peroxidation of lipid membranes, which increases their susceptibility to the action of 
cPLA2. 
 
AA may affect a host of cellular processes directly and indirectly via downstream 
pathway recruitment. There is increasing evidence that alterations in the cPLA2 
activity are able to modulate myocardial AA levels. Firstly, the peroxidized 
metabolites of AA could exert inherent toxic effects.  Secondly, the enzymes that 
metabolize AA produce reactive oxygen species (Burton et al., 1990). Prostaglandins 
have been reported to exert both detrimental and beneficial actions on the 
ischaemic/reperfused heart, whilst leukotrienes are considered to induce negative 
actions on cardiac function, through vasoconstriction (Van der Vusse et al., 1997). 
However, these conditions can be excluded in a cell culture setting, since no external 
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sources such as invading neutrophils are present. Interestingly, external AA 
administration to ischaemic neonatal cardiomyocytes proved to be cytoprotective 
(Engelbrecht et al., 2005). Other reports have shown that cardiac phospholipid 
metabolism is compromised in the ischaemic heart. In situ experiments in canine heart 
showed that accumulation of AA is most prominent in the subendocardial layers of 
the ischaemic left ventricle, hence the region with the highest degree of 
underperfusion (Van der Vusse et al., 1997). Restoration of flow to ischaemic tissue 
further increases cardiac AA levels. Furthermore, the post-ischaemic accumulation of 
AA correlates positively with lactate dehydrogenase, a marker for irreversible loss of 
cellular integrity, suggesting a relation between the degree of ischaemic damage and 
the extent of AA accumulation (Van der Vusse et al., 1997). AA administration 
affected the amplitude of the Ca2+ transient in cardiac myocytes and reduced the 
contraction rate (Van der Vusse et al., 1997). Furthermore, myocardial ischaemia 
results in accelerated phospholipid catabolism, which leads to the accumulation of 
amphiphilic metabolites in critical subcellular loci, which precipitate 
electrophysiologic dysfunction and myocyte cell death (Hazen et al., 1991).  
 
On the other hand, it has been suggested that the overwhelming majority of 
measurable phospholipase A2 activity in the heart is the calcium-independent iPLA2 
isoform (McHowat and Creer, 2004). A 10 fold induction of iPLA2 during brief 
myocardial ischaemia has been reported (Hazen et al., 1991). The complexity of the 
signalling cascade and the identification of numerous mechanisms for cPLA2 
activation are further complicated by the overlapping expression of multiple PLA2 
enzymes with interdependent actions within the cell. For example it has been 
suggested that cPLA2 might be important in modulating the activity of iPLA2 
(McHowat and Creer, 2004).  
 
The cPLA2-/- mouse has demonstrated the importance of cPLA2 in various 
physiological processes. Despite profound defects in the fertility of female cPLA2-/- 
mice, macrophages derived from these mice failed to make leukotrienes and 
prostaglandins. In septic patients, plasma PLA2 activity is elevated and is correlated 
with the severity of organ dysfunction and mortality. When sepsis is induced and 
measured in the rat heart, a 60% cPLA2 activity increase was observed during late 
sepsis (Tong et al., 1998). Recently, a safeguarding role of cPLA2 has been suggested, 
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due to its pathway coupling to ß2-adrenergic receptors in the human heart. Upon ß2-
adrenergic receptor stimulation, cPLA2 translocates to caveolae functional platforms 
where it facilitates phosphorylation of endothelial nitric oxide synthase (Ait-Mamar et 
al., 2005).  
 
4. Mitogen activated protein kinases (MAPK) and ischaemic    
         preconditioning 
 
4.1. Introduction  
 
Several protein kinase pathways are activated during cell injury caused by myocardial 
ischaemia and ischaemia/reperfusion. They capacitate in the onset of cell injury and 
the reduction of this injury by ischaemic and pharmacologic preconditioning.  One of 
the primary pathways involved in this context is the MAPK pathway. MAPKs are a 
conserved family of enzymes which transduce extracellular signals into intracellular 
responses. The MAPK pathway is activated by ligand binding to receptor-associated 
tyrosine kinases (RTKs) and requires the activation of guanidine triphosphate- (GTP) 
binding proteins (Lazou et al., 1998). Receptor binding causes RTK monomer 
dimerisation and phosphorylation of tyrosine residues on the cytosolic domain 
(Chakraborti and Chakraborti, 1998). This activation stimulates the cytoplasmic 
MAPKs sequentially (Chakraborti and Chakraborti, 1998). Each pathway follows the 
same conserved module, namely: a MAPK kinase kinase (MEKK) is activated and 
phosphorylates a MAPK kinase (MEK or MKK) via serine/threonine 
phosphorylation. MKK is a dual specificity kinase and phosphorylates MAPK at a 
threonine and tyrosine residue. All of the MAPKs are activated by dual 
phosphorylation of a serine and a threonine residue by a MAPK kinase (Michel et al., 
2001). The three major MAPKs in the myocardium are the 42 and 44 kDa 
extracellular signal-regulated kinases (ERK1/2), as well as the two stress-activated 46 
and 54 kDa c-Jun N- terminal kinases (JNK 1/2) and the 38 kDa p38 kinases (Cohen 
et al., 2000) . Not only are they role players in preconditioning (Maulik et al., 1996; 
Clerk et al., 1998), but p38 and ERK also have the capacity to phosphorylate cPLA2 
and thus contribute to its optimal activity (Gijon et al., 1999). Therefore, these two 
MAPK deserve special attention within the scope of this study.  
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4.2. MAPK activation and ischaemic preconditioning 
 
4.2.1. ERK activation and ischaemic preconditioning 
 
It has been shown that ERK is activated in ischaemia, however, a fundamental role for 
ERK activation in cardioprotection is controversial. It is known that ERK mediates 
cell growth and survival signals (Burgering and Bos, 1995). The role of ERK as a 
potential mediator of IPC has been controversial although the majority of studies 
suggest a role for ERK in IPC (Omura et al., 1999; Liu et al., 2003).  PKC is the 
upstream activator of ERK as well as ROS. In response to a preconditioning stimulus, 
ERK translocates to the nucleus, where it has been demonstrated to activate NFkB 
and AP-1 (Hobbie et al., 1997; Hausenloy and Yellon, 2006). In IPC two phases of 
ERK activation have been described, the first one immediately post-IPC stimulus and 
the second one at reperfusion. When inhibiting the first activation phase, the second 
one was abolished, providing evidence that phase one activation might serve as an 
execution requirement for ERK phosphorylation at reperfusion.  Activation of ERK-
1/2 at reperfusion, following a prolonged ischaemic event, protects the heart against 
ischaemia/reperfusion injury (Hausenloy et al., 2004). Hausenloy et al. (2004) 
demonstrated a 4 fold increase in ERK activation at 15 min into reperfusion, which 
was preceeded by a 35 min ischaemic period. It has been shown that inhibition of 
ERK enhances ischaemia/reperfusion induced cell death, whilst a sustained activation 
contributes to adaptive cytoprotection in cultured neonatal cardiomyocytes (Yue et 
al., 2000). Liu and co-workers (2003) have demonstrated that ERK is strongly 
activated in neonatal cardiomyocytes at 10 min and 30 min after hypoxic 
preconditioning with a downregulation of phosphorylation at 60 min post hypoxic 
preconditioning (Liu et al., 2003). In this model the protective effects of hypoxic 
preconditioning were completely abolished by PD98059, a selective inhibitor of 
MEK-1/2, an upstream activator of ERK.  
  
4.2.2. p38 activation and ischaemic preconditioning 
 
Most focus has been on the p38 MAPK cascade with most controversy and confusion 
regarding its scope of action in the context of IPC (Steenbergen, 2002). Two of the at 
least 6 known p38 isoforms, namely p38α and p38β are expressed in cardiac muscle. 
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p38 is activated by sustained ischaemia followed by reperfusion as well as by short 
episodes of ischaemia. However, p38´s contribution to benefit the ischaemic heart is 
controversial. Some studies have shown that preconditioning activates p38 MAPK 
during ischaemia and when inhibiting it, protection is lost, suggesting a clear 
protective role of p38 in the preconditioning context (Yellon and Downey, 2003). 
Within the course of ischaemia, however, the level of p38 is reduced towards pre-
ischaemic values, followed by another phosphorylation period at reperfusion. It is of 
importance that in ischaemia in non preconditioned hearts no p38 activation per se is 
observed. Furthermore, in many studies it was shown that inhibition of p38 leads to a 
higher degree of resistance against ischaemic injury in non-preconditioned tissue. To 
add to the confusion, p38 inhibition blocked preconditioning induced protection 
(Yellon and Downey, 2003). 
 
Yue and co-workers (2002) have shown protection in isolated rat hearts with the p38 
activator menadione. They suggested a role for ROS which could activate p38 in a 
similar manner. p38, in turn through phosphorylation of the HSP27, would stabilize 
stress fibres and thereby conferring resistance to ischaemic associated osmotic 
swelling, associated with ischaemia in the heart (Yue et al., 2002). It was also shown 
that myocardial ischaemia and reperfusion activate p38 MAPK in vivo (Feuerstein 
and Young, 2000). It was demonstrated that ischaemia alone increases p38 
moderately by 3,5 fold over the baseline while reperfusion further increases p38 
MAPK by 6,3 fold in the rabbit heart, perfused via the Langendorff system 
(Feuerstein and Young, 2000). Interestingly, activation of p38 is a rapid event 
occurring within minutes, and precedes cellular and organ lesions. Importantly, 
administration of the p38 MAPK inhibitor SB203580 before the ischaemic event 
improved functional parameters: it accelerated the recovery of coronary flow, 
contractility and left ventricular pressure (Feuerstein and Young, 2000).   
  
The described results in the literature make it clear that different models such as 
simulated ischaemia, ischaemia/reperfusion and hypoxia have a differential potency 
and outcomes. The investigation of hypoxia and hypoxia/reoxygenation of rat 
neonatal ventricular myocytes by Seko and co-workers (1997) revealed that both 
conditions caused rapid p38 activation (Seko et al., 1997). Here, the p38 
phosphorylation reached maximum levels after 2 to 5 min hypoxia and again after 5 to 
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10 min reoxygenation (Seko et al., 1997). Other studies, on the other hand, have 
demonstrated that IPC reduces p38 activity during ischaemia, and pharmacological 
inhibition of p38 activity during ischaemia/reperfusion is cardioprotective (Marais et 
al., 2001). This implies a detrimental role of p38 MAPK in ischaemia/reperfusion.  
 
Taking these findings together, IPC can activate or reduce p38 MAPK during the 
prolonged ischaemic event. A generally accepted view is that IPC transiently activates 
p38 MAPK during the preconditioning phase and reduces its activation during the 
prolonged ischaemic event. Four isoforms of p38 have been described: p38α, p38β, 
p38γ and p38δ. The different p38 isoforms, their expression pattern and different 
experimental models and protocols, as well as usage of different species have been 
suggested to be the reason for the conflicting findings (Yellon and Downey, 2003). It 
has been implied that different p38 isoforms mediate different adaptive responses. 
Both p38α MAPK and p38β MAPK mRNA have been detected in the heart. Evidence 
suggests that p38α MAPK activation may be coupled to apoptosis whereas p38β 
MAPK activation may be coupled to protective cellular responses (Wang et al., 1998; 
Saurin et al., 2000). This is in agreement with the observation that overexpression of 
p38α results in apoptosis in cardiomyocytes (Wang et al., 1998). Others explain the 
differential outcome with differential p38 activation dynamics and suggest that the 
duration of p38 activation determines its cellular function. Mackay and co-workers 
(2000) showed that extended p38 activation during ischaemia leads to cell death in 
neonatal rat cardiomyocytes (Mackay and Mochly-Rosen, 2000). They demonstrated 
a higher susceptibility to cell death from ischaemia in a dose and time dependent 
manner by modulating p38 activity with a tyrosine phosphatase inhibitor (Mackay and 
Mochly-Rosen, 2000).    
 
4.2.3 JNK activation and ischaemic preconditioning 
 
The role of JNK in IPC is also controversial, since both protective and detrimental 
activities have been described. The majority of reports suggest that JNK is activated 
only during reperfusion after ischaemia but not affected by ischaemia alone (Sugden 
and Clerk, 1998). Sato and co-workers (2000) describe an increase of JNK in isolated 
rat hearts exposed to 30 min ischaemia followed by 2 h of reperfusion (Sato et al., 
2000). In anesthetized rabbits submitted to a preconditioning protocol JNK’s 
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phosphorylation was observed after 20 min of sustained ischaemia (Iliodromitis et al., 
2002). In ischaemically injured porcine ileum mucosa as a model for intestinal 
ischaemia, it was shown that ERK1/2 and p38 positively regulate recovery from 
ischaemia, whilst JNK mediates negatively recovery from ischaemia (Shifflett et al., 
2004).  
 
In summary, although literature supports a potential role for ERK, p38 MAPK and 
JNK in preconditioning (Clerk et al., 1998), contrary reports are available. These 
conflicting results may be due to the use of different experimental models. Due to the 
discussed role of the different MAPKs in preconditioning and their differential 
capacity to phosphorylate cPLA2, we did not look into more detail at JNK activation. 
 
5. Myocyte cell death  
 
5.1. Introduction 
 
Two principal avenues leading to myocyte death have been described, namely 
necrosis and apoptosis. Necrosis is characterized by cell swelling and blebbing and 
disruption of the sarcolemmal and mitochondrial membrane (Clerk et al., 2003). 
Furthermore, active transmembrane ion transport systems are slowed down, leading to 
increased cell membrane permeability with alterations in ion distribution for K+, Na+ 
and Ca2+. This loss of ion concentration gradients leads to loss of control of cell 
volume regulation, causing swelling of cell organelles which will lead to their 
disruption and subsequent lysis (van Wijk and Hageman, 2005). Also, activated 
proteases and elevated Ca2+ levels may alter mitochondrial respiratory function 
causing increased production of reactive oxygen species (van Wijk and Hageman, 
2005). This unregulated process produces cellular debris and subsequently leads to the 
induction of inflammation. 
 
Apoptosis, on the other hand, is an extremely well regulated and controlled form of 
cell death – therefore, termed programmed cell death - which results in a systematic 
cellular dismantling without inducing inflammation. Cells undergoing apoptosis have 
characteristic morphological features such as nuclear condensation and fragmentation 
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as well as the formation of apoptotic bodies (Clerk et al., 2003). A key phenomenon 
of apoptotic cell death is the activation of a unique class of aspartate specific 
proteases known as caspases. Caspases can be grouped in an upstream (effector 
caspases-1, -2, -4, -5, -8, -9, -10) and a downstream (executioner caspases-3, -6, -9) 
subgroup. One of the substrates for caspase-3 is the repair enzyme PARP, yielding a 
85 kDa inactive fragment which is a useful marker for activation of caspases during 
apoptosis (Piot et al., 1999). The function of caspase-3 mediated cleavage of PARP is 
to protect the pool of energetic substrates against the use of these substrates by PARP 
(Yang et al., 2000). Cleavage of PARP by caspase-3 during apoptosis facilitates 
nuclear disassembly and may help to ensure the completion of apoptosis. Therefore, 
when PARP is cleaved by caspases, the ATP “wasting” repair attempt is paused and 
apoptosis can be executed (Szabo, 2005). Importantly, a systemic inflammatory 
response is prevented.  
 
How much decision making the cell capacitates in choosing a specific death avenue 
depends on the intracellular environment, such as the metabolic status and energy 
content, the pH and [Ca2+] and the redox potential, all dictating the final outcome of 
cellular fate (Clerk et al., 2003). 
 
5.2. PARP activation-shift towards necrosis 
 
In contrast to PARP cleavage, PARP activation induces necrotic cell death. The 
obligatory trigger for its activation is nicks and breaks in the DNA strand. The 
generation of free radicals and oxidants in cardiac myocytes during 
ischaemia/reperfusion leads to such DNA strand breakage. This initiates an energy 
consuming and inefficient metabolic cycle with transfer of the ADP-ribosyl moiety of 
NAD+ to protein acceptors. Resynthesis of NAD+ requires ATP and poses a heavy 
demand on the cellular energy capacities. Failure to overcome this crisis leads to cell 
death, apoptotic or necrotic, depending on ATP availability.  In this way, ATP is 
rapidly diminishing and its usage for other processes, including apoptosis is 
prevented. Therefore, the energy depletion caused by PARP activation induces rapid 
necrotic rather than delayed apoptotic cell death, in other words, PARP activation 
shifts cellular death towards necrosis, away from apoptosis. In this way PARP may 
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prevent several damaged cells from attempting to repair themselves and surviving 
with a high mutation frequency (Martin et al., 2005).  
 
PARP activation due to ROS, such as superoxide anions, hydroxyl radicals and 
hydrogen peroxide contributes to myocardial and vascular injury. In H9c2 cardiac 
myoblasts it has been shown that oxidant injury via hydrogen peroxide application 
causes PARP activation with subsequent reduction in mitochondrial respiration. This 
suppression was ameliorated when pharmacologically inhibiting PARP. Also, hypoxia 
and reoxygenation, without other stress components used in simulated ischaemia, 
resulted in PARP activation. Furthermore, PARP activation in neonatal rat cardiac 
myocytes has been observed in nitric oxide induced cell necrosis, which was also 
ameliorated by pharmacological PARP inhibition (Szabo, 2005). 
 
The activation of PARP can lead to massive NAD+ usage that correlates with changes 
in the cellular NAD+ amount (Szabo and Dawson, 1998). Although necrosis induction 
is fast, it induces a systemic inflammatory response. This scenario can only be 
avoided through cleavage and inactivation of PARP. 
 
5.3. Caspase- and PARP cleavage in context of I/R injury 
 
Both ischaemia and reperfusion increase the production of ROS, the first through 
mitochondrial respiratory mechanisms, the second through degradation of energetic 
substrates (van Wijk and Hageman, 2005). ROS react directly with biological 
molecules, such as lipid membranes, proteins and DNA and create a disturbance in 
ROS homeostasis and a further generation of ROS (van Wijk and Hageman, 2005).  
ROS produced during ischaemia and reperfusion induce DNA strand breaks which 
leads to over-activation of PARP.  
 
It was also shown in ischaemia/reperfusion experiments, that the reoxygenation 
induced suppression of the myocardial contractility is dependent on the functional 
integrity of PARP. The activation of PARP might be contributing to the development 
of reperfusion injury in the heart (Szabo and Dawson, 1998) since it creates a non-
beneficial energetic environment for the cell. Multiple lines of evidence implicate 
PARP in the pathogenesis of heart failure. In fact, one of the best characterized 
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pathways is PARP activation in relation to myocardial energy metabolism. Within the 
muscle contraction context, myocardial contraction is especially tightly regulated. 
Disruption of cellular or mitochondrial energetics leads to elevated intracellular Na+ 
and Ca2+ levels and progressive acidosis (Szabo, 2005).  
 
In the ischaemia/reperfusion setting a rather prolonged time course of PARP 
activation has been observed, present at 1 h after start of reperfusion and continuously 
present as late as 24 h after reperfusion. Cell death in this context can either be of 
necrotic or apoptotic nature or a combination of both. Especially the time of apoptosis 
initiation is still to a large extent unknown. In experiments exposing cells to 6 h 
ischaemia without reperfusion showed no DNA fragmentation (Freude et al., 2000). 
Therefore, it has been hypothesised that the “point of no return” could be situated 
farther downstream in the apoptotic cascade. Forty five min of ischaemia resulted in 
reversible injury and 90 min in irreversible ischaemic injury. In irreversible injury, 
caspase-3 activation and PARP cleavage were present after ischaemia whilst in 
reversible injury, neither caspase-3 activation, nor PARP cleavage was present 
(Freude et al., 2000). It can be deducted that activation of caspase-3 and cleavage of 
PARP are early events in ischaemia; and that DNA fragmentation occurs only in late 
reperfusion, representing the end-stage within the apoptotic cascade (Freude et al., 
2000). Therefore, inhibition of apoptosis should be undertaken early in ischaemia. 
In neonatal cardiomyocytes, simulated ischaemia induced caspase-3 activation and 
PARP cleavage, preceded by any morphological signs of apoptosis, confirming that 
the apoptotic cascade is activated early during ischaemia, after 5 min, but is executed 
only after reperfusion (Engelbrecht et al., 2004).  
When preconditioning rat hearts with five 5 min cycles followed by 30 min of 
coronary occlusion and 180 min reperfusion, cleavage of caspase-3 and inactivation 
of PARP were prevented (Piot et al., 1999). It was also found that apoptosis was 
reduced by preconditioning rabbit cardiomyocytes. These data suggest that IPC 
reduces irreversible ischaemic injury partly by decreasing apoptosis after prolonged 
ischaemia and reperfusion.  
The molecular mechanisms by which caspases carry out the execution of apoptosis 
are complex and require many enzymes and cofactors. However, the caspase 
dependent apoptotic pathway is not the only one indicated in I/R injured tissues. In 
the presence of the overall caspase inhibitor Z-DEVD-FMK, which is able to inhibit 
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caspase-1, -3 and -4, nuclear fragmentation was also present and although reduced, 
significant tissue damage was present (van Wijk and Hageman, 2005). Therefore, 
caspase-independent pathways have been suggested. On the other hand Z-DEVD-
FMK attenuated ischaemia/reperfusion injury in rat hearts (van Wijk and Hageman, 
2005).   
 
5.4. PARP in the context of inflammation 
 
Of special interest is the fact that PARP can exert profound effects on inflammatory 
mediators and downstream processes. Recent studies have implicated PARP in local 
as well as systemic inflammatory conditions. PARP inhibition has been shown to 
suppress TNF-α production in the late stage of myocardial reperfusion injury. 
Furthermore, inhibition of PARP suppresses the development of rheumatoid arthritis 
in rodent models and improves the survival rate of mice injected with a high dose of 
endotoxin. 
  
These findings are surprisingly similar to the earlier discussed context of TNF-α and 
inflammation in the myocardium and in rheumatoid arthritis. One can expect that 
PARP dependent regulation of NF-κB activation has a broad effect on the expression 
of proinflammatory genes. In vitro and in vivo experiments indicate that inhibition of 
PARP activation exerts effects on the expression, activation and nuclear translocation 
of key proinflammatory genes and proteins. (Yang et al., 2000) The absence or 
inhibition of PARP suppresses the activation of MAPKs and NFκB. Consequently, 
PARP inhibition interferes with the expression of proinflammatory genes such as the 
inducible nitric oxide synthase (iNOS). Furthermore, inhibition of PARP is associated 
with a reduction in neutrophil infiltration in the site of injury in myocardial 
reperfusion. This is of importance since these cells mediate the TNF-α response from 
the systemic side.  
 
5.5. Clinical application 
 
Evidence suggests that inhibition of PARP is beneficial, especially in the early phase 
of myocardial reperfusion injury. Genetic disruption of PARP provides marked 
protection against delayed myocardial ischaemia and reperfusion injury (Yang et al., 
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2000). Due to the central role of PARP in the decision making of cell death, a primary 
objective would be to shift cell death from necrosis towards apoptosis, for two 
reasons. Firstly, apoptosis buys out lethal time, which “in the mean time” would have 
been “used” for a fast necrotic cell death. This increases the chance to rescue the 
tissue, if the “point of no return” in the death cascade has not yet been reached. It 
implies however, that reperfusion injury needs to be understood in the context of 
various stages in the apoptotic cascade. Secondly, it prevents a systemic response 
involving the whole organism, which via the inflammatory cascade would provide 
positive feedback into the tissue of injury, as seen in cytokines and heart failure. 
PARP-1 has currently reached the stage of phase I/II clinical testing as cardioprotector 
and sensitizer for chemotherapy (Graziani et al., 2005).  
 
6. Crosstalk 
 
6.1. Introduction 
  
In ischaemia/reperfusion injury, increased cellular Ca2+ and the production of reactive 
oxygen species (ROS) may cause cell death by intrinsic apoptotic pathways or by 
necrosis. Both the activity of cPLA2 and the actions of TNF-α are closely interwoven 
within this context. We have dealt with their individual roles in ischaemic injury, but 
one has to consider a crosstalk between them, since this mirrors the more cell 
physiological approach. Can a molecular link be established between TNF-α and 
cPLA2 signalling, directing the decision making of cellular death via PARP and 
caspase-3? On several points within the stress response pathways, the key signalling 
components, viz TNF-α, cPLA2, MAPK, caspase-3 and PARP interlink or overlap, 
especially within the context of inflammation and apoptotic cell death. Therefore, in 
this chapter I would like to shed light onto possible interdependencies of these role 
players, whether they jointly modulate the cytoprotective effect as described in TNF-α 
preconditioning.  
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6.2. TNF-α receptor binding directs apoptosis and inflammation 
 
6.2.1 Inflammation via cPLA2 
  
The most potent stimuli that elicit apoptosis in cardiomyocytes are amongst others 
oxygen radicals, cytokines, stress conditions such as ischaemia, (especially when 
followed by reperfusion) as well as physical or chemical stress and sphingolipid 
metabolites (Feuerstein and Young, 2000). Cardiac myocyte apoptosis varies between 
0.1-30% depending on the disease specimen, methodology and model employed as 
well as area of sampling (Feuerstein and Young, 2000). In general, apoptosis is not 
found with inflammation, as these two conditions, the pro-apoptotic and 
proinflammatory effects of TNF-α can be seen as mutually exclusive.  It has been 
suggested that caspases are the molecular tool used by TNF-α to control the 
proinflammatory response. Most cellular TNF-α responses, including cPLA2 
activation, are mediated by TNFR1 and CD95. Both of these receptors also mediate 
apoptosis, whilst the important proinflammatory mediator AA is generated via cPLA2.  
The adapter proteins on the cytosolic side of the receptor provide a modularity that 
allows flexible regulation of signalling events which needs to direct the two 
conflicting pathways:  apoptosis versus inflammation (Kronke and Adam-Klages, 
2002). If the ATP dependency in an ischaemically challenged cell plays a role in 
shifting apoptotic death towards necrotic death, then this exact receptor modularity 
should be a crucial decision maker between life and death for the cardiomyocyte. It 
has been suggested that TNF-α induces cPLA2 phosphorylation and activation, which 
is triggered through the death domain and involves adapter proteins that result in the 
activation of Raf-1 and ERK (Kronke and Adam-Klages, 2002) (Figure 1.8.). This 
mode of action would mediate the inflammatory response. The involvement of MAP 
kinases in the control of cPLA2 and AA release has been described by 
Gudmundsdottir et al (2001).  They have found that agonist stimulated endothelial 
cells treated with MAPK inhibitors, PD98059 (ERK inhibitor) and SB203580 (p38 
inhibitor), showed decreased arachidonic acid release and cPLA2 activity. Further 
evidence substantiating the role of ERK activation through TNF-α was provided by 
Lüschen and co-workers (2000), who have demonstrated that TNF-α dependent 
activation of ERK and cPLA2 requires the intact death domain of the receptor TNF-
R55 (Luschen et al., 2000). The same team has also shown that in murine fibroblasts 
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cPLA2 is phosphorylated in response to TNF-α by ERK only, not by p38 MAPK, 
suggesting a molecular link from the receptor via the death domain to ERK and 
cPLA2 (Luschen et al., 2000). It has been shown that MAPK-activating death domain 
protein (MADD) and receptor-interacting protein 2 (RIP2) can interact with the death 
domain to mediate ERK activation (Luschen et al., 2000). Furthermore, it was shown 
in a murine fibroblast cell line that inhibition of p38 enhanced TNF-α induced cell 
death and led to the activation of caspase-3. Overexpression of p38 did not protect the 
cells from TNF-α induced cytotoxicity (Luschen et al., 2004).  
 
6.2.2. Apoptosis via cPLA2 cleavage 
 
Interestingly, cPLA2 belongs to the family of enzymes which can be cleaved by 
certain caspases, namely by caspase-3, -7 and -8. This renders a cleavage product of 
70 and 32 kDa after cleavage of the caspase-3 motif at amino acids 519-522. This 
control mechanism could be responsible for TNF-α mediated cytoprotection, escaping 
the detrimental inflammatory response leading to necrotic cell death, but rather 
shifting the stress response towards apoptosis. The multiple cPLA2 cleavage sites for 
various caspases would ensure its cleavage, thus leading to apoptosis. It has been 
shown that cleavage of cPLA2 resulted indeed in the inactivation of its enzymatic 
activity (Kronke and Adam-Klages, 2002).  In TNF-α stimulated human embryonic 
kidney (HEK) cells an increase in cPLA2 activity was seen after caspase-3 inhibition, 
suggesting a role for caspases to downregulate or terminate cPLA2 activation. 
Interestingly, caspase-3 has been shown to be essential for vimentin proteolysis (Slee 
et al., 2001), a structural protein associated with cPLA2 translocation (Murakami et 
al., 2000).  
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Figure 1.8. TNF-α mediated activation and inactivation of cPLA2 (modified from  
(Kronke and Adam-Klages, 2002).  
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6.3. Modulation of contractility and gene expression via TNF-α and cPLA2 
 
Another point of signalling overlap between cPLA2 and TNF-α has been shown by 
Amadou and co-workers (2002). Investigating the role of AA as mediator of TNF-α 
on Ca2+ transients and contractility in rat cardiomyocytes, the key role of cPLA2 and 
the AA pathway in mediating contractile effects of TNF-α is apparent, with a TNF-α 
dose dependent outcome (Amadou et al., 2002). 10 ng/ml TNF-α produced a 40% 
increase in the amplitude of Ca2+ transient and myocyte contraction, whilst a higher 
dose (50 ng/ml) TNF-α evoked a biphasic effect, an initial positive effect followed by 
a sustained negative effect. Both the positive and negative effects could be reproduced 
by AA and blocked by AACOCF3 (10 µM), pre-incubated for 15 min. Another study 
substantiating the crosstalk between cPLA2 and TNF-α, even on the gene expression 
level, was shown by Thommessen and co-workers (1998). They demonstrated that 
TNF-α induced activation of NF-κB was inhibited by a selective cPLA2 inhibitor 
AACOCF3 (Thommesen et al., 1998). A human skin keratinocyte cell line which was 
pre-treated for 1h with AACOCF3, before stimulating with 10 ng/ml TNF-α, showed a 
70% reduction in NFκB activation (Thommesen et al., 1998).  
 
6.4. cPLA2, AA and apoptosis 
 
Programmed cell death is associated with changes in glycerophosholipid metabolism. 
In some cells undergoing apoptosis, AA release parallels the reduction in cell viability 
and DNA fragmentation (Taketo and Sonoshita, 2002). AA release has also been 
associated with TNF-α induced apoptosis. It has been shown that cPLA2 is critical in 
the cytotoxic actions of TNF-α via metabolites of AA. ROS are generated by the 
peroxidation of arachidonic acid metabolites. This fast available source for oxygen 
radicals is thought to be involved in TNF-α induced cytotoxicity. TNF-α rapidly 
stimulates PLA2 within 5-10 minutes post-receptor binding and subsequently 
increases AA release (Prabhu, 2004). AA might be responsible for the dual contractile 
effect of TNF-α, since PLA2 inhibition abrogates both the positive and negative 
inotropic responses induced by TNF-α. AA initially induced a direct 
cardiostimulatory effect which was followed by sphingomyelinase activation and 
downstream negative inotropy. In vitro and isolated cell studies indicate that cytokine 
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mediated PLA2 activation precedes sphingomyelin hydrolysis and that AA activates 
sphingomyelinase.  
 
6.5. Aims and Hypothesis  
 
Taking the findings of this literature survey into synthesis, a crosstalk of the 
mentioned role players is apparent. The aim of the present study is to investigate this 
exact crosstalk of cPLA2 in the context of TNF-α as a preconditioning mimetic. We 
hypothesize a role for cPLA2 in TNF-α mediated cytoprotection, possibly on the level 
of cPLA2 activation and phosphorylation, or through a specific cPLA2 translocation.  
 
The role of cPLA2 will be described in a threefold manner:  
 
• its activation via phosphorylation,  
• its translocation to sub-cellular structures  
• its turnover through caspase mediated cleavage  
 
The interplay of cPLA2 with the MAPKs p38 and ERK as possible contributors to 
cPLA2 phosphorylation and activation will also be investigated. Sub-cellular cPLA2 
translocation will be monitored and co-localized with the nuclear envelope and the 
endoplasmic reticulum.  Furthermore, cPLA2 in the context of ischaemically induced 
cell death will be evaluated, monitoring cell viability as well as caspase-3 and PARP 
activation. At the same time this will allow us to investigate cPLA2 turnover 
regulation via caspase-3 mediated cPLA2 cleavage. This will shed light on the 
survival mechanisms employed by the ischaemically challenged cell in a setting of 
TNF-α mediated cytoprotection.  
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Chapter 2: Materials and Methods 
 
2.1. Materials and Reagents 
 
Highly purified recombinant murine TNF-α was purchased from CytoLab (Israel), the 
cPLA2 inhibitor arachidonyl trifluoromethyl ketone (AACOCF3) from Calbiochem 
(USA) and the caspase inhibitor Z-Asp(O-Me)-Glu(O-Me)-Val-Asp(O-Me) 
fluoromethyl ketone (Z-DEVD-FMK) from SIGMA-ALDRICH (South Africa). The 
following antibodies as well as the caspase-3 transfection- and silencing kit were 
obtained from Cell Signaling Technology (MA, USA): cPLA2 antibody and phospho-
cPLA2 antibody (Ser 505), p38 MAPK antibody and phospho-p38 MAPK 
(Thr180/Tyr182) antibody, p44/42 MAPK antibody and phospho-p44/42 MAPK 
(Thr202/Tyr204) antibody, cleaved caspase-3 antibody (Asp 175) and PARP 
antibody. Antibodies to nucleoporin p62 and calnexin were purchased from Santa 
Cruz Biotechnology (California, USA). Tissue culture tubes, 50 ml and 15 ml were 
used from Greiner Bio-One (Germany). Sterile serological pipettes (25ml and 10ml) 
were obtained from LP Italiana SPA and Sterilin Ltd. Pipette tips were purchased 
from Greiner Bio-One. Culture medium, Dulbecco’s modified Eagle’s medium 
(DMEM) was obtained from Highveld (South Africa), trypsin and phosphate buffered 
saline (PBS) from SIGMA-ALDRICH (South Africa) and tissue culture flasks and -
dishes, cell scraper and microcentrifuge tubes were purchased from  Greiner Bio-One 
(Germany). Eight chamber slides were used from Nunc Lab-Tek (USA). Syringe 
milipore filter, trypan blue reagent, albumine bovine serum (BSA) and Bradford 
reagent were obtained from SIGMA-ALDRICH (South Africa). For the gel 
electrophoresis a Mini-Protean BIO RAD system was used. Ammonium persulfate 
was purchased from SIGMA-ALDRICH (South Africa), Acrylamide/bis-Acrylamide 
from Promega (South Africa) and N,N,N,N’-Tetramethylethylenediamine from 
MERCK (Germany).  
 
2.2 Cell Culture 
 
C2C12 mouse myoblasts (European Collection of Cell Cultures - ECACC), seeded at 
12 000/cm2, were cultured in Dulbecco’s modified Eagle’s medium supplemented 
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with 10 % fetal calf serum, 4% glutamine and 1% penicillin/streptomycin in a 
humidified atmosphere, 37°C, in the presence of 5% CO2. In detail, cells were washed 
with 0.01 M sterile PBS, typsinized (0.25% Trypsin – EDTA), centrifuged for 3 min 
at 6000 x g and seeded as follows: 3x105 myoblasts per 25 cm² tissue culture flask, 
1x105 myoblasts per culture dish in six-well plate and 2x104 myoblasts per 8 chamber 
slide. Myoblast differentiation was induced when cells reached approximately 70% 
confluency, by replacing the growth medium with a low serum differentiation 
medium (DMEM supplemented with 1 % filter sterilized horse serum).  
Differentiation medium was changed every 48 hours.  
 
2.3. Experimental protocol 
 
On day 8, 9 and 10 of differentiation, terminally differentiated myotubes were 
randomly divided into 6 groups: 1. control (Con), 2. simulated ischaemia (SI), 3. 
ischaemic preconditioning (IPC), 4. TNF-α preconditioning (TNF-α PC), 5. TNF-α + 
inhibitor (AACOCF3 or Z-DEVD-FMK) and 6. inhibitor only (AACOCF3 or Z-
DEVD-FMK). 
 
Control cells were kept under normoxic conditions and 5% CO2. The period of 
simulated ischaemia (1% O2, 5% CO2) lasted for 8 hrs. IPC cells were washed with 
sterile PBS and prior to the simulated ischaemic event pre-incubated for 30 min with 
filter sterilized modified Esumi buffer (Esumi et al., 1991), pH 6.2, containing (in 
mM): 137 NaCl, 12 KCl,  0.5 MgCl2, 0.9 CaCl2, 20 Hepes, under hypoxic conditions, 
1% O2 and 5% CO2, followed by a 60 min washout time under normoxic conditions 
and differentiation medium, before submitted to the simulated ischaemic event. TNF-
α PC cells were pre-incubated with 0.5ng/ml TNF-α in differentiation medium under 
normoxic conditions, followed by a 60 min washout period before the simulated 
ischaemic event. The same procedure was followed for group 5 and 6, (0.5ng/ml 
TNF-α + 10µM AACOCF3/10µM Z-DEVD-FMK or the inhibitors only) respectively. 
Following the washout phase, cells were washed twice with PBS and submitted to the 
simulated ischaemic event, using modified Esumi buffer + 20 mM 2-Deoxy-D-
Glucose (2-DG) pH 6.4 (Figure 2.3.). 2-DG inhibits glycolysis irreversibly and limits 
cellular metabolic capacity. The control cells received the same handling- and PBS 
washing steps and received differentiation medium.  
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2.3.1 Treatment of cells with AACOCF3 and Z-DEVD-FMK 
 
Arachidonyl trifluoromethyl ketone (AACOCF3) (10µM dissolved in ethanol), an 
inhibitor of cPLA2 or Z-Asp (O-Me)-Glu(O-Me)-Val-Asp(O-Me) fluoromethyl 
ketone (Z-DEVD-FMK) (10µM dissolved in DMSO), an inhibitor of caspase-3, -6, -
7, -8, and -10 was added to the cells in differentiation medium for 30 min under 
normoxic conditions and 5% CO2 followed by a 60 min washout phase in 
differentiation medium, prior to the simulated ischaemia.  
 
2.3.2. Capase-3 silencing  
 
Cells were transfected with 100 nM caspase-3 siRNA on day 6 of differentiation. 200 
µl fresh differentiation medium was added to a microcentrifuge tube together with 4 
µl transfection reagent and incubated at room temperature for 5 min.  12 µl caspase-3 
siRNA was then added and gently mixed through pipetting up and down, followed by 
a 5 min incubation period at room temperature. The mixture was the added to 1000µl 
differentiation medium, which was added to the cells, followed by a 48 hour 
incubation period under normoxic conditions and 5% CO2. Cells were then washed 
with fresh differentiation medium and submitted to the experimental protocol, where 
caspase-3 silenced cells were preconditioned with and without 0.5 ng/ml TNF-α. The 
caspase-3 silencing control cells received the same handling- and PBS washing steps 
and received differentiation medium. 
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Fig.2.3. Schematic representation of experimental protocol with the groups: 1. control 
(Con), 2. simulated ischaemia (SI), 3. ischaemic preconditioning (IPC), 4. TNF-α 
preconditioning (TNF-α PC), 5. TNF-α + inhibitor (         AACOCF3/Z-DEVD-FMK) 
and 6. inhibitor (Inh) only (AACOCF3/Z-DEVD-FMK). SI lasted for 8 hrs. 
Ischaemic- or TNF-α preconditioning lasted for 30 min followed by a 60 min washout 
period.  
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2.4. Trypan blue viability assay 
 
The trypan blue exclusion technique (Kitakaze et al., 1997) was used to determine 
viability of C2C12 cells. Non-viable cells are unable to prevent the entrance of the 
blue dye into the cytoplasm due to membrane leakage, while it is excluded in viable 
cells due to an intact, functional cellular membrane. In brief, following simulated 
ischaemia, Esumi buffer was removed and cells were trypsinized through adding 
0.25% trypsin, warmed up to 37ºC. Following a 3 min incubation time at 37ºC, cells 
were microscopically observed for detachment from the culture dish surface. To 
remove the trypsin and to neutralize the cell solution, cells were micro-centrifuged 
briefly at maximum speed, supernatant was taken off and cells were re-suspended in 
100µl PBS. 100 µl trypan blue solution (4%) in PBS was added, and solutions were 
carefully mixed through re-suspension. Cells were immediately counted on the 
haemacytometer (Neubauer, Olympus, CKX31). The number of dark to total cells was 
calculated and viability expressed as a percentage of total cells counted.  
 
2.5. Western blot analysis 
 
2.5.1 Protein extraction 
 
After completion of the experimental protocol, cells were rapidly placed on ice, 
Esumi buffer was removed and cells were carefully washed with cold PBS. Total 
myotube protein was extraceted with a lysis buffer (modified 
radioimmunoprecipitation (RIPA) buffer), pH 7.4, containing (in mM): Tris/HCl 2.5, 
ethylenediaminetetraacetic acid 1 (EDTA), NaF 50, NaPPi 50, dithiothreitol-1 (DTT), 
Phenylmethylsulfonyl fluoride (PMSF) 0.1, benzamidine 1,4 µg/ml soybean trypsin 
inhibitor (SBTI), 10 µg/ml leupeptin, 1% NP40, 0.1% SDS, 0.5% Na Deoxycholate. 
260µl lysis buffer was added to the culture flask and cells were removed from the 
plastic surface using a cell scraper. Cell lysates were stored for short periods at -20°C 
in microcentrifuge tubes. 
 
2.5.2. Bradford Protein quantitation 
The rapid and sensitive method for the quantitation of microgram quantities of protein 
utilizing the principle of protein-dye binding, Bradford, was employed (Bradford, 
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1976). It involves the binding of Coomassie Brilliant Blue G-250 to protein, which 
causes a shift in the absorption maximum of the dye from 465nm to 595 nm. The 
increase in absorption at 595nm is monitored, using a spectrophotometer (Cary 
Varian).  
   
Cell lysates were defrosted, kept on ice and sonicated for 5 seconds at power level 3 
(Vir Sonic 300, Virtis Gardiner) followed by centrifugation for 10 min at 4°C and 
5000 x g (ALC-PK121R) in order to pellet cell debris and to expose the whole 
cellular protein fraction. For the establishment of a standard curve, a protein dilution 
series was set up, pipetting 2µg, 4µg, 8µg, 12µg, 12µg, 16µg and 20µg albumin 
bovine serum dissolved in PBS (BSA, 200µg/ml) and 900µl Bradford reagent into test 
tubes, adjusted to 1000µl with deionized water. Sample protein concentrations were 
determined through pipetting 5µl of the sample supernatant with 900µl Bradford 
reagent and adjusted to 1000µl with 95µl deionized water.   
 
Test tube content was mixed by vortexing, incubated for 5 min at room temperature 
and the absorbance was measured at 595nm wavelength against a reagent blank 
prepared from 900 µl Bradford reagent and 100µl deionized water, using semi-micro 
cuvettes. The weight of protein in µg/ml was plotted against the absorbance and 
protein concentration was determined.  
 
2.5.3. Sodium-dodecyl-sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Laemmli sample buffer were prepared, using a sample buffer containing (in M): TRIS 
0.5, pH 6.8, 10 % SDS, 2.5 ml glycerol, 0.2ml 0.5% bromophenol blue, deionized 
water. 150 µl mercaptoethanol was then added to 850 µl sample buffer. Cell lysates 
were boiled for 5 min and shortly spun in a microcentrifuge to assure complete 
sample acquisition. 20µg total protein was separated by 10% sodium-dodecyl-sulfate-
polyacrylamide-gel-electrophoresis (SDS-PAGE) and a 4% stack gel.  
 
2.5.4. Western Blot analysis 
 
After completion of the protein separation, proteins were transferred to a PVDF 
membrane (ImmobilonTM P, Millipore) using a semi dry blotting system (BIO RAD 
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trans-blot SD). 3 blotting buffers were prepared using for the anode buffer 1 (in M): 
Tris-base 0.3, pH 10.4, 20% methanol; for the anode buffer 2 (in mM): Tris-base 25, 
pH 10.4, 20% methanol and for the cathode buffer (in mM): Tris-base 25, ε-
aminohexanoic acid 40, pH 9.4, 20% methanol. The PVDF membrane was soaked in 
methanol for 15 sec, allowed to dry and then soaked in anode buffer 2. On the anode 
plate four blotting papers were placed, after being soaked in anode buffer 1. Two 
blotting papers, soaked in anode buffer 2 were added, followed by the PVDF 
membrane and the gel, removed of its stack gel. Six blotting papers, soaked in 
cathode buffer, were added. To avoid air bubbles, the blotting sandwich was rolled 
with a clean wet glass tube. The system’s cathode lid was tightly closed and the 
transfer proceeded with 0.5 A, 15 V for 60 min.       
 
Following the protein transfer, non-specific binding sites on the membranes were 
blocked for 120 min at room temperature with 5% fat free milk in Tris-buffered 
saline-0.1% Tween 20 (Polyoxyethylenesorbitan monolaurate, Tween 20) (TBST). 
Followed by a washing step with TBST, the membranes were incubated overnight at 
4°C with the primary antibodies that recognize phospho-specific cPLA2 (Ser505), 
ERK-p42/p44 (Thr202/Tyr204), p38-MAPK (Thr180/Tyr182), caspase-3 (p17 fragment 
pAb) and PARP (p85 fragment pAb). The primary antibody dilution was in each case 
1:1000, diluted in TBST.  
 
Membranes were subsequently washed with large volumes of TBST (3x5 min) and 
the immobilized antibody conjugated with a 1:10 000 diluted horseradish peroxidase-
labelled secondary antibody (Amersham Life Sciences), incubated for 50-60 min at 
room temperature. After thorough washing with TBST, membranes were incubated at 
room temperature for 1 min with ECLTM detection reagents (Amersham Life 
Sciences) and quickly exposed to an autoradiography film (HyperfilmTM) to detect 
light emission through a non-radioactive method (AXIM fixer/developer).  
 
2.5.5. Film analysis  
 
Films were densitometrically analysed (UN-SCAN-IT, Silkscience) and corrections 
were made for background noise.  
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2.6. Immunocytochemistry labelling  
 
All solvents and buffers for the labelling were made up fresh and filter sterilized, to 
ensure that they are maximum particle free.  
 
Cells were grown on autoclaved cover glasses which were placed into the culture 
dish. After completion of the experimental protocol 30 min into the ischaemic event, 
cells were gently washed with 0.1 M PBS and fixed using 1000 µl fixative per culture 
dish, made up as methanol/acetone in a 1:1 ratio. Culture dishes were incubated for 10 
min on ice at 4˚C and then left to air-dry for 20 min at room temperature. Dried cover 
glasses were then gently rinsed with 1ml PBS and transferred to microscope slides.  
 
For the rest of the labelling procedure slides were kept in light protected humidified 
staining chambers. The slides were then incubated at room temperature for 20 min 
with 5 % donkey serum in PBS, 100 µl per cover glass, to block non specific binding 
sites. Serum was then drained and primary antibody goat polyclonal nucleoporin p62 
or goat polyclonal calnexin and rabbit polyclonal phospho-cPLA2 (Ser505) were added 
in a 1:50 PBS dilution and 50 µl volume and incubated for 90 min at room 
temperature. The application of the agents was performed in a manner that that a fluid 
bubble with a convex meniscus due to the fluid surface tension could occur without 
leaking of fluid from the cover glasses. For the controls for the staining procedure 50 
µl PBS was used instead of primary antibody. The slides were then carefully washed 
with 1 ml PBS per slide and secondary antibody FITC or Texas Red (Jackson, donkey 
anti rabbit/donkey anti goat) was added in a 1:200 dilution and 50 µl volume to all 
slides, including the PBS controls. To avoid crystals, the secondary antibody was 
briefly centrifuged and the supernatant was used for the labelling. Following 30 min 
incubation at room temperature, 50 µl of the nuclear stain Hoechst, 10 mg/ml (Sigma) 
was added additionally in a 1:200 dilution and incubated for another 10 min at room 
temperature. Cover glasses were then carefully washed 3 times with 1000 µl PBS and 
transferred to glass microscope slides, mounted with fluorescent mounting medium 
(Dako Cytomation) and finally sealed with commercially available nail polish. Slides 
were then analysed and stored in silver foil at -20 ˚C.      
 
 
 56
2.6.1. Fluorescence intensity analysis 
 
For the fluorescence image acquisition of the microscope slides, a Nikon eclipse E 
400 microscope was used. Acquisition was performed under the same camera settings 
in terms of sensitivity and exposure time, using the Nikon ACT-1 software. The focal 
plane was selected using the Hoechst filter setting, to avoid unnecessary photo 
bleaching. P-cPLA2 intensity was observed using the FITC filter setting. Images were 
taken with a 10x, 20x, 40x objective for documentation and with a 100x oil 
immersion objective for the intensity analysis, selecting 2 myotubes per field, for 6 
random fields, in 4 independent experiments. Therefore, the data represent a total of 
48 myotubes per experimental group.     
 
Image analysis was performed employing the Simple PCI-C-Imaging Systems 
software. Images were loaded, and with the Shapes Toolbar the region of interest 
(ROI) tool was selected. The whole cell including the nuclei and the nuclei with 
overlayed cytoplasmic signal were separately analysed for mean fluorescence 
intensity and then subtracted, in order to calculate the mean nuclear intensity only, 
without cytoplasmic background signal. Data expressed in arbitrary pixel values were 
exported to Microsoft excel and statistically analysed.   
 
2.6.2. z- stack analysis 
 
In z-stack (3D) experiments stacks of images are acquired at different focal planes, 
which enable the construction of a three-dimensional image. This allows navigation 
through the image and the view in x, y and z dimensions separately in the slice 
viewer.   
 
For the z stack analysis cells were grown in 8-chamber slides (Nunc) following the 
same labelling protocol as employed for the microscope slides. Image acquisition was 
performed using an Olympus IX 81 microscope equipped with the Cell^R software. 
Through setting up a defined experiment in the Experiment Manager, image 
acquisition parameters such as exposure time, illumination settings and emission filter 
cube selection were kept constant for all groups and ensured appropriate selection of 
parameters. The DAPI 360 nm excitation wave length was used for setting the focal 
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plane, avoiding unnecessary photo-bleaching. For the experiment setting a combined 
multi color image frame was selected, using 360 nm DAPI for the nuclear stain 
Hoechst, 492 nm FITC for nucleoporin p62 or calnexin and 572 nm TxRed for the 
pcPLA2 as multiple excitation settings. Through the z-stack frame the top and bottom 
focus position parameter were selected, indicating the upper and lower dimensions of 
the cell and a step width of 0.26 µm between the image levels was chosen.  
 
2.6.3. Co-localization analysis 
 
z-stack images were loaded into the image buffer and the two fluorescences to be 
measured were activated in the image navigatior button bar. Through the co-
localization button bar the threshold for the first and second fluorescence was set. Co-
localization was then calculated and displayed as a new false-color image. An Excel 
data sheet with co-localization area was generated.  
 
2.7. Statistical analysis 
 
The results are expressed as mean values ± SEM and were analyzed by one-way 
Analysis of Variance (ANOVA) with the Bonferroni correction. The α-level was 0.05. 
The statistics software Graph Pad Prism 2.01 was employed to perform statistical 
tests. Data were considered to be statistically significant with a p value <0.05.   
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Chapter 3: Results 
 
3.1. Experimental measurements after 8 hrs simulated ischaemia 
 
3.1.1. Cell viability after 8 hrs simulated ischaemia 
 
To investigate the cytoprotective effect of 0.5 ng/ml TNF-α on C2C12 myotubes, 
cellular viability was assessed after the 8 hrs simulated ischaemic event, using the 
trypan blue exclusion method. As shown in Figure 3.1.1., control cells are highly 
viable (81.6±2.0%), whilst exposure to simulated ischaemia (SI) was potent enough to 
reduce viability significantly [24.8±3.9% (p<0.05)]. A significant increase in viability 
compared to SI was observed in cells exposed to IPC [57.6±3.7% (p<0.05)] and TNF-
α PC [65.8±3.4% (p<0.05)].  
 
In order to study the involvement of cPLA2 in the protection conferred by TNF-α we 
used AACOCF3 to inhibit cPLA2. We undertook investigations to reveal the 
involvement of cPLA2 in TNF-α mediated cytoprotection, using the C2C12 cell line, a 
murine skeletal muscle cell line as model for cardiac tissue, based on previous work 
of peers as well as on findings described in skeletal muscle preconditioning studies 
performed by Pang et al (1996). The C2C12 model is an established and recognized 
model for cardiac and skeletal muscle tissue.  
 
The inhibitor conferred cytoprotection significantly [52.8±1.9% (p<0.05)] with 
viability values close to those seen in the IPC group. The inhibitor applied together 
with 0.5 ng/ml TNF-α also conferred cytoprotection [53.7±1.1% (p<0.05)], with 
values similar to those seen when using the cPLA2 inhibitor only. The vehicle effect 
was ruled out, since appropriate experiments with the solvent, ethanol, did not show 
any effect.  
 
3.1.2. cPLA2 phosphorylation after 8 hrs simulated ischaemia 
 
The phosphorylation pattern of cPLA2 following 8 hrs simulated ischaemia was 
assessed using Western blot analysis, reflecting the whole cell protein fraction. Data 
are expressed as % of control (Figure 3.1.2.). Compared to the control 
phosphorylation level, a significant downregulation in cPLA2 phosphorylation in IPC 
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[20.3±5.2% (p<0.05)] and TNF-α PC [45.3±5.0% (p<0.05)] can be observed. In SI 
cPLA2 phosphorylation is similarly decreased [41.1±0.5% (p<0.05)].  
 
To assess a possible modulatory effect of caspase-3 on cPLA2 phosphorylation or 
cPLA2 cleavage, the caspase inhibitor Z-DEVD-FMK (10µM) was employed.  Under 
the effect of this inhibitor, cPLA2 phosphorylation was almost completely inhibited, 
with significantly less cPLA2 phosphorylation [3.7±0.7% (p<0.05)] compared with the 
TNF-α PC group. This inhibitory effect however was overwritten, when using Z-
DEVD-FMK in the presence of 0.5 ng/ml TNF-α [35.2±0.5 (p<0.05)].  
 
3.1.3. Caspase-3- and PARP cleavage after 8 hrs simulated ischaemia 
 
In order to investigate the recruitment of the apoptotic pathway after 8 hrs simulated 
ischaemia, caspase-3 cleavage (Figure 3.1.3.) and PARP cleavage (Figure 3.1.4.) were 
assessed through Western blot analysis. Figure 3.1.3. indicates clearly, that compared 
to control levels, caspase-3 is cleaved showing the 17 kDa cleaved product, reaching 
significance in the SI group [194.8±7.9% (p<0.05)] as well as in the TNF-α PC group 
[229.0±13.2% p<0.05)]. The caspase inhibitor applied in the presence of 0.5 ng/ml 
TNF-α significantly increases caspase-3 cleavage [339.2±15.6% p<0.05)] compared 
to TNF-α PC only. The caspase inhibitor reduces caspase-3 cleavage [99.1±18.6] 
towards the control level, indicating its physiological activity. 
 
The 116 kDa PARP protein levels were analyzed. The less dense this band the more 
PARP has been cleaved, reducing the 116 kDa signal intensity. Compared to the 
PARP control level significant decreases in total PARP in the SI [43.8±1.0% 
(p<0.05)], IPC [34.9±3.1% (p<0.05)] and TNF-α PC groups [33.7±2.6% p<0.05)] 
were observed. The caspase inhibitor induced PARP cleavage, however, significantly 
less than seen in the previous 3 groups [71.2±3.9% (p<0.05)]. When the caspase 
inhibitor is employed in the presence of 0.5 ng/ml TNF-α, significantly less total 
PARP is observed [56.9±8.7% (p<0.05)] compared to the PARP signal seen with the 
caspase inhibitor only; however, it is a significantly stronger PARP signal in the TNF-
α + Inh (Z-DEVD-FMK) group compared with SI, IPC and TNF-α PC.  
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Figure 3.1.1. Viability in % following simulated ischaemia showing control (Con), 
simulated ischaemia (SI), ischaemic preconditioning (IPC), TNF-α preconditioning 
(TNF-α PC), TNF-α + Inh and inhibitor only. SI lasted for 8 hrs. Ischaemic- or TNF-α 
preconditioning lasted for 30 min followed by a 60 min washout period. 
Inh=AACOCF3. * p<0.05 vs Con, # p<0.05 vs SI, n=6.  
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Figure 3.1.2. cPLA2 phosphorylation following simulated ischaemia showing control 
(Con), simulated ischaemia (SI), ischaemic preconditioning (IPC), TNF-α 
preconditioning (TNF-α PC), TNF-α + Inh and inhibitor (Inh) only. SI lasted for 8 
hrs. Inh= Z-DEVD-FMK. * p<0.05 vs Con, # p<0.05 vs SI, n=6.  
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Figure 3.1.3. Caspase-3 cleavage indicated through the 17 kDa fragment following 
simulated ischaemia showing control (Con), simulated ischaemia (SI), ischaemic 
preconditioning (IPC), TNF-α preconditioning (TNF-α PC), TNF-α + Inh and 
inhibitor (Inh) only. SI lasted for 8 hrs. Inh = Z-DEVD-FMK. * p<0.05 vs Con, # 
p<0.05 vs IPC, § p<0.05 vs TNF-α PC, n=6. 
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Figure 3.1.4.   PARP cleavage indicated through the 116 kDa fragment following 
simulated ischaemia showing control (Con), simulated ischaemia (SI), ischaemic 
preconditioning (IPC), TNF-α preconditioning (TNF-α PC), TNF-α + Inh and 
inhibitor (Inh) only. SI lasted for 8 hrs. Inh= Z-DEVD-FMK.* p<0.05 vs Con, # 
p<0.05 vs IPC, n=6. 
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Figure 3.1.5. Non-successful caspase-3 silencing. Caspase-3 cleavage indicated 
through the 17 kDa fragment following simulated ischaemia showing control (Con), 
simulated ischaemia (SI), ischaemic preconditioning (IPC), TNF-α preconditioning 
(TNF-α PC), TNF-α + caspase-3 silencing (TNF-α + Sil), caspase-3 silencing only 
(Sil) and caspase-3 silencing control (SilCon). SI lasted for 8 hrs, n=1. 
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3.2. 5 min into simulated ischaemia 
 
3.2.1. cPLA2 phosphorylation at 5 min into the simulated ischaemic event 
 
At 5 min into the ischaemic event, the cPLA2 phosphorylation pattern was 
investigated. In order to find a cross talk between caspase-3 and the degree of cPLA2 
phosphorylation, the caspase inhibitor Z-DEVD-FMK was employed. Compared to 
the control levels, no statistically siginificant differences were observed (Figure 
3.2.1.). Since the phosphorylation band was very weak in all groups, the effect of the 
cPLA2 inhibitor could not be evaluated.   
 
3.2.2. ERK and p38 phosphorylation at 5 min into the simulated ischaemic event 
 
It is suggested in the literature that both p38 MAPK and ERK can phosphorylate 
cPLA2. We therefore investigated the phosphorylation pattern of both MAPK at 5 min 
into the ischaemic event. To elucidate the cPLA2 activation pathway in context of 
TNF-α preconditioning, we employed a caspase inhibitor (Z-DEVD-FMK) and a 
cPLA2 inhibitor (AACOCF3) in the presence of 0.5 ng/ml TNF-α as well as the 
inhibitor only. However, at the chosen time point no significant changes in the ERK 
phosphorylation pattern were observed (Figure 3.2.2.a.). When investigating p38 
phosphorylation we found a weak pp38 signal in the control group; however the 
phosphorylation did not reach significance compared with the other groups (Figure 
3.2.2.b.). However we did find a significant increase in p38 phosphorylation when 
employing the caspase inhibitor alone [96.2±13.4% (p<0.05)] or in presence of 0.5 
ng/ml TNF-α [102.3±22.4% (p<0.05)] compared to the pp38 signal observed when 
employing the cPLA2 inhibitor in presence of 0.5 ng/ml TNF-α. 
 
3.2.3 Caspase-3- and PARP cleavage at 5 min into the simulated ischaemic event 
 
The observation of caspase-3 or PARP cleavage early within the ischaemic event 
enables us to dissect out the onset of the apoptotic pathway induction. As can be seen 
in Figure 3.2.3.a. we can observe a very interesting trend in caspase-3 cleavage, which 
however does not reach statistical significance at that time point. The extent of 
caspase-3 cleavage in the Con and SI group is very small, indicated by a faint band of 
the 17 kDa cleaved caspase-3 unit. However, we find a trend towards caspase-3  
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Figure 3.2.1. cPLA2 phosphorylation at 5 min into the ischaemic event,  showing 
control (Con), simulated ischaemia (SI), ischaemic preconditioning (IPC), TNF-α 
preconditioning (TNF-α PC), TNF-α + Inh 1 and inhibitor 1 (Inh 1) only as well as 
TNF-α + Inh 2 and inhibitor 2 (Inh 2) only. Inh 1 = AACOCF3, Inh 2 = Z-DEVD-
FMK, n=6. No significant changes were observed.  
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Figure 3.2.2.a.   ERK phosphorylation at 5 min into the ischaemic event,  showing 
control (Con), simulated ischaemia (SI), ischaemic preconditioning (IPC), TNF-α 
preconditioning (TNF-α PC), TNF-α + Inh 1 and inhibitor 1 (Inh 1) only as well as 
TNF-α + Inh 2 and inhibitor 2 (Inh 2) only. Inh 1 = AACOCF3, Inh 2 = Z-DEVD-
FMK, n=6. No phosphorylation of ERK was observed.  
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Figure 3.2.2.b. p38 phosphorylation at 5 min into the ischaemic event,  showing 
control (Con), simulated ischaemia (SI), ischaemic preconditioning (IPC), TNF-α 
preconditioning (TNF-α PC), TNF-α + Inh 1 and inhibitor 1 (Inh 1) only as well as 
TNF-α + Inh 2 and inhibitor 2 (Inh 2) only. Inh 1 = AACOCF3, Inh 2 = Z-DEVD-
FMK, n=6. * p<0.05 vs TNF-α + Inh 1. (The graph is a reflection of all conducted 
experiments, which is not in all cases coherently reflected in the western blot image).  
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cleavage in both the IPC and TNF-α PC group. The caspase-3 inhibitor did not affect 
caspase-3 cleavage yet, indicated by a much stronger signal. When looking at PARP 
cleavage at the same time point (Figure 3.2.3.b.), we find no significant differences 
between the groups, indicating that PARP cleavage is not executed that early in 
ischaemia. This is to be expected, since caspase-3 cleavage is a prerequisite for PARP 
cleavage to take place. 
 
3.3. 30 min into simulated ischaemia 
 
3.3.1. cPLA2 phosphorylation at 30 min into the simulated ischaemic event 
 
A second appropriate time window in the ischaemic event was chosen, to investigate 
cPLA2 phosphorylation- and activity changes. Even at 30 min into simulated 
ischaemia, no significant changes of cPLA2 phosphorylation were observed (Figure 
3.3.1.).  
 
3.3.2. ERK and p38 phosphorylation at 30 min into the simulated ischaemic   
          event 
 
The phosphorylation of p38 and ERK MAPK was investigated at 30 min into 
simulated ischaemia. As shown in Figure 3.3.2.a., a significant increase in ERK 
phosphorylation can be observed when using AACOCF3 alone [283.2±30.8% 
(p<0.05)] or in presence of 0.5 ng/ml TNF-α [312.9±31.3% (p<0.05)], compared to 
control levels. This also reaches significance when compared to the SI group. The 
caspase inhibitor Z-DEVD-FMK alone [46.9±16.1%] or in presence of 0.5 ng/ml 
TNF-α [55.1±21.5%] prevents ERK phosphorylation, keeping the level similar to 
control levels. This reaches significance when comparing with the groups using 
AACOCF3 alone or in presence of 0.5 ng/ml TNF-α.  
 
When looking at p38 phosphorylation, we find a significant increase in the IPC group 
compared to SI (Figure 3.3.2.b.). This increase in phosphorylation is however not 
statistically significant when comparing to control levels. The increase in p38 
phosphorylation in IPC also reaches significance when comparing with TNF-α + Inh 
1- or 2; and Inh 1- or 2 only.  
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Figure 3.2.3.a. Caspase-3 cleavage at 5 min into the ischaemic event,  showing 
control (Con), simulated ischaemia (SI), ischaemic preconditioning (IPC), TNF-α 
preconditioning (TNF-α PC), TNF-α + Inh 1 and inhibitor 1 (Inh 1) only as well as 
TNF-α + Inh 2 and inhibitor 2 (Inh 2) only.  Inh 1 = AACOCF3, Inh 2 = Z-DEVD-
FMK, n=6. No significant changes were observed.  
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Figure 3.2.3.b. Total PARP at 5 min into the ischaemic event,  showing control 
(Con), simulated ischaemia (SI), ischaemic preconditioning (IPC), TNF-α 
preconditioning (TNF-α PC), TNF-α + Inh 1 and inhibitor 1 (Inh 1) only as well as 
TNF-α + Inh 2 and inhibitor 2 (Inh 2) only. Inh 1 = AACOCF3, Inh 2 = Z-DEVD-
FMK, n=6. No significant changes were observed.  
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3.3.3. Caspase-3- and PARP cleavage at 30 min into the simulated ischaemic   
          event 
 
The trend of caspase-3 cleavage as seen at the 5 min time point, is clearly mirrored at 
the 30 min time point into the ischaemic event (Figure 3.3.3..a). However, no 
statistical significance is reached. The trend displays an increase in caspase-3 
cleavage in the order SI, IPC and TNF-α PC. A clear decrease in caspase-3 cleavage 
is seen when employing the cPLA2 inhibitor AACOCF3 alone or in presence of 0.5 
ng/ml TNF-α. Subsequently, we do not find any significant changes in the PARP 
cleavage pattern, as reflected by a similar strong signal of the 116 kDa band seen in 
all groups (Figure 3.3.3.b.).    
 
3.4. Vehicle controls  
 
To verify that there was no effect of the solvents ethanol and DMSO used for the 
cPLA2 inhibitor AACOCF3 and the caspase inhibitor Z-DEVD-FMK respectively, 
phosphorylation- and cleavage pattern of the proteins of interest were assessed.  
Figure 3.4. shows that a vehicle effect could be ruled out.  
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Figure 3.3.1. cPLA2 phosphorylation at 30 min into the ischaemic event,  showing 
control (Con), simulated ischaemia (SI), ischaemic preconditioning (IPC), TNF-α 
preconditioning (TNF-α PC), TNF-α + Inh 1 and inhibitor 1 (Inh 1) only as well as 
TNF-α + Inh 2 and inhibitor 2 (Inh 2) only. Inh 1 = AACOCF3, Inh 2 = Z-DEVD-
FMK, n=6. No significant changes were observed.  
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Figure 3.3.2.a. ERK phosphorylation at 30 min into the ischaemic event,  showing 
control (Con), simulated ischaemia (SI), ischaemic preconditioning (IPC), TNF-α 
preconditioning (TNF-α PC), TNF-α + Inh 1 and inhibitor 1 (Inh 1) only as well as 
TNF-α + Inh 2 and inhibitor 2 (Inh 2) only. Inh 1 = AACOCF3, Inh 2 = Z-DEVD-
FMK, n=6. * p<0.05 vs Con, # p<0.05 vs SI, § p<0.05 vs TNF-α + Inh 2 and Inh 2 
only.  
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Figure 3.3.2.b. p38 phosphorylation at 30 min into the ischaemic event,  showing 
control (Con), simulated ischaemia (SI), ischaemic preconditioning (IPC), TNF-α 
preconditioning (TNF-α PC), TNF-α + Inh 1 and inhibitor 1 (Inh 1) only as well as 
TNF-α + Inh 2 and inhibitor 2 (Inh 2) only.  Inh 1 = AACOCF3, Inh 2 = Z-DEVD-
FMK, n=6. * p<0.05 vs SI, # p<0.05 vs TNF-α + Inh 1- and 2; and Inh 1- and 2 only. 
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Figure 3.3.3.a. Caspase-3 cleavage at 30 min into the ischaemic event,  showing 
control (Con), simulated ischaemia (SI), ischaemic preconditioning (IPC), TNF-α 
preconditioning (TNF-α PC), TNF-α + Inh 1 and inhibitor 1 (Inh 1) only as well as 
TNF-α + Inh 2 and inhibitor 2 (Inh 2) only. Inh 1 = AACOCF3, Inh 2 = Z-DEVD-
FMK, n=6.  Although a trend has been observed, no significant changes were present.  
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Figure 3.3.3.b. Total PARP at 30 min into the ischaemic event,  showing control 
(Con), simulated ischaemia (SI), ischaemic preconditioning (IPC), TNF-α 
preconditioning (TNF-α PC), TNF-α + Inh 1 and inhibitor 1 (Inh 1) only as well as 
TNF-α + Inh 2 and inhibitor 2 (Inh 2) only. Inh 1 = AACOCF3, Inh 2 = Z-DEVD-
FMK, n=6. No significant changes were observed.  
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Figure 3.4. Vehicle controls for the proteins of interest, showing the control group 
(Con), simulated ischaemia at 5 min (SI 1), Z-DEVD-FMK vehicle (DMSO) at 5 min 
ischaemia (Veh 1a), AACOCF3 vechile (ethanol) at 5 min ischaemia (Veh 1b), 
simulated ischaemia at 30 min (SI 2), Z-DEVD-FMK vehicle (DMSO) at 30 min 
ischaemia (Veh 2a) and AACOCF3 vehicle (ethanol) at 30 min ischaemia (Veh 2b). 
No effects of the vehicle on the phosphorylation- and cleavage pattern were observed.  
Total cPLA2 
pcPLA2 
Total ERK
pERK 
Total p38
pp38 
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3.5. Immunocytochemistry  
 
In order to investigate the translocation pattern of phosphorylated cPLA2, 
immunocytochemistry was performed. A high magnification (100 x oil immersion) 
was chosen, to enable the identification of subcellular regions involved in pcPLA2 
signalling events. The nuclear stain HOECHST was employed to indicate the nuclear 
region.   
 
3.5.1. cPLA2 phosphorylation and mean nuclear intensity at 30 min into the    
          simulated  ischaemic event 
 
Figure 3.5.1.a. and 3.5.1.b. clearly indicate a differential pcPLA2 signal in the nuclear 
region in the different groups, indicated with the HOECHST nuclear stain. Without 
performing any analysis, the SI myotubes appeared to show a very strong nuclear 
pcPLA2 signal, compared to the control group. TNF-α PC displayed a weak nuclear 
signal, similar to the control group. IPC displayed a stronger nuclear signal, but 
weaker then the SI group.  
 
Via the selection of a region of interest (ROI), the mean nuclear intensity was 
compared (Figure 3.5.c). Results verify the nuclear intensity profile perceived with 
the “unarmed” eye. SI showed a significant increase in mean nuclear intensity 
[40.6±5.4 (p<0.05)], compared with the control group [15.9±2.2]. In IPC [27.3±1.3 
(p<0.05)] and TNF-α PC [25.4±3.2 (p<0.05)] significantly less nuclear intensity was 
observed, compared to the SI group.   
 
3.5.2. cPLA2 phosphorylation and 3 D z-stack fluorescence imaging at 30 min    
          into the simulated ischaemic event 
 
The z-stack technique enabled the construction of a 3 dimensional myotube image, to 
observe pcPLA2 translocation more in depth. As seen in Figure 3.5.2.a. and 3.5.2.b., 
the pcPLA2 translocation pattern in all four groups mirrors the results described using 
the other labelling and image acquisition techniques (Figure 3.5.1.a. and 3.5.1.b.). 
Maximum nuclear intensity is seen in SI, whilst TNF-α PC shows fluorescence 
intensity close to the control levels. Furthermore, it was observed that pcPLA2 
translocates to the peri- and endonuclear region. It also seems that IPC shows a 
stronger nuclear signal than TNF-α PC; however, as seen in Figure 3.5.1.c., this does 
not even reach statistical significance compared to the Con group intensity.  
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Figure 3.5.1.a. C2C12 myotubes labeled with pcPLA2/FITC, displayed in green and 
the nuclear indicator HOECHST, displayed in blue. The figure shows control (Con), 
simulated ischaemia (SI), ischaemic preconditioning (IPC) and TNF-α 
preconditioning (TNF-α PC).  
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Figure 3.5.1.b C2C12 myotubes labeled with pcPLA2/FITC only. The figure shows 
control (Con), simulated ischaemia (SI), ischaemic preconditioning (IPC) and TNF-α 
preconditioning (TNF-α PC).  
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Figure 3.5.1.c Mean cPLA2 fluorescence nuclear intensity is shown in control (Con), 
simulated ischaemia (SI), ischaemic preconditioning (IPC) and TNF-α 
preconditioning (TNF-α PC). * p<0.05 vs Con, # p<0.05 vs SI, n=4.  
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3.5.3. Co-localization of pcPLA2 and nucleoporin p62, 3 D z-stack imaging at    
           30 min into the simulated ischaemic event 
 
In order to verify nuclear translocation of pcPLA2, a nuclear marker protein, 
nucleoporin p62 was chosen (Figure 3.5.3.a.) together with the co-localization 
technique. Cells were co-labelled for nucleoporin p62 and pcPLA2, a z-stack was 
acquired with a step width of 0.26 µm and co-localization area was determined by the 
software, generating a new image (Figure 3.5.3.b.). The results (Figure 3.5.3.c.) show 
a significant increase in co-localization area in the SI group [5.8±0.3% (p<0.05)] 
compared to control levels. Furthermore, a significantly reduced co-localization area 
is observed in IPC [2.2±0.3% (p<0.05)] and TNF-α PC [1.7±0.2% (p<0.05)] 
compared to the area in the SI group.  
 
3.5.4. Differential pcPLA2 translocation to endoplasmic reticulum (ER) in SI?  
 
When carefully observing Figure 3.5.1.b., a clustered or punctuate fluorescence signal 
pattern can be seen in the SI group, representing pcPLA2. To investigate whether SI 
induces a differential translocation response, possibly involving the endoplasmic 
reticulum (ER) as target organelle, labelling for the ER was performed. The marker 
protein for this organelle, calnexin, was chosen. The image (Figure 3.5.4.) indicates a 
similar punctuate or cluster fluorescence signal pattern for calnexin, as seen in SI for 
pcPLA2. This provides preliminary evidence for a differential organelle targeting 
mechanism in SI, including not only the nucleus but also the ER.   
 
3.6. DVD 
 
Due to the nature of the acquired data as well as space limiations, a data DVD is 
attached with accompanying image and movie clip material. The DVD contains z-
stack movies of pcPLA2, pcPLA2 and nucleoporin; and pcPLA2 and calnexin; as well 
as the co-localization z-stacks showing of each the control (Con), simulated ischaemia 
(SI), ischaemic preconditioning (IPC) and TNF-α preconditioning (TNF-α PC). 
Furthermore the PBS-control stains are included.  
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Figure 3.5.2.a. C2C12 myotubes labeled with pcPLA2/TexRed and HOECHST. The 
figure shows control (Con), simulated ischaemia (SI), ischaemic preconditioning 
(IPC) and TNF-α preconditioning (TNF-α PC) in slice view with x, y and z spatial 
dimensions.   
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Figure 3.5.2.b. C2C12 myotubes labeled with pcPLA2/TexRed only. The figure 
shows control (Con), simulated ischaemia (SI), ischaemic preconditioning (IPC) and 
TNF-α preconditioning (TNF-α PC) in slice view with x, y and z spatial dimensions.   
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Figure 3.5.3.a. C2C12 myotube labelled for nucleoporin p62, FITC linked. 
Nucleoporin is displayed in green, indicating the nuclear pores and nuclear network.   
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Figure 3.5.3.b. Co-localization of pcPLA2 and nucleoporin p62, based on z-stack 
imaging at 30 min into the simulated ischaemic event. Displayed are control (Con), 
simulated ischaemia (SI), ischaemic preconditioning (IPC) and TNF-α 
preconditioning (TNF-α PC). Co-localization area is displayed in yellow, pcPLA2 in 
red and nucleoporin p62 in green.  
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Figure 3.5.3.c. Co-localization area of pcPLA2 and nucleoporin p62, based on z-stack 
imaging at 30 min into the simulated ischaemic event. Displayed are control (Con), 
simulated ischaemia (SI), ischaemic preconditioning (IPC) and TNF-α 
preconditioning (TNF-α PC), * p<0.05 vs Con, # p<0.05 vs SI, n=3.  
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Figure 3.5.4. Labelling control myotubes with the endoplasmic reticulum (ER) 
marker protein calnexin (green fluorescence signal in left image) results in a clustered 
or punctuate cytosolic signal pattern. A similar clustered or punctuate pattern can be 
observed in SI, when staining for pcPLA2 (green fluorescence signal, right image).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SI Con 
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Chapter 4: Discussion 
 
The aim of this study was to examine the involvement of cPLA2 signalling in TNF-α 
mediated cytoprotection. Therefore, multiple levels of cPLA2 signalling were 
addressed. Firstly, to assure the cytoprotective effect of the employed low dose TNF-
α and to verify the cell line’s capacity for ischaemic preconditioning, cell viability 
assessment was performed. Secondly, as possible contributors to cPLA2 activation, 
the phosphorylation pattern of p38 MAPK and ERK were investigated at appropriate 
time points. Thirdly, to dissect out the cPLA2 interplay and dependencies on these 
MAPKs within the pathway context, the selective cPLA2 inhibitor AACOCF3 was 
employed and its effect on cell viability was examined. Furthermore, to substantiate 
cPLA2 activation, we assessed its cellular distribution, translocation and target 
preference fluorescence microscopically, using co-localization and z-stack techniques. 
Additionally we examined the apoptotic pathway induction through analysing 
caspase-3 and PARP cleavage. Finally, to address a recently introduced mechanism of 
a caspase-3 related modulation on the cPLA2 turnover, we employed the caspase 
inhibitor, Z-DEVD-FMK.  
 
4.1. Model 
 
In order to investigate the cPLA2 signalling events in the course of ischaemia and 
TNF-α preconditioning without interference or alterations from other cell types, we 
made use of a tissue culture model. Our model combines the following properties of 
ischaemia: Inhibition of glycolysis, which irreversibly prevents the degree of ATP 
synthesis in the cytosol and reduces the availability of NADH; a significant reduction 
of the pH of the buffer, inducing a decrease of intracellular pH, similar to that in other 
models of ischaemia. Additionally, environmental hypoxia of 1% O2 was used.  
 
The use of differentiated myotubes subjected to simulated ischaemia has some 
obvious advantages but also some disadvantages compared to in vivo ischaemia. The 
major advantages of this approach are that heterogeneity of ischaemic-induced 
damage is kept to a minimum, which is of special importance in TNF-α and 
inflammatory mediator induced signalling, due to induced feed back mechanisms 
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involving other inflammatory cells. Due to the fact that the C2C12 cell line is an 
established and recognized model used for cardiac and skeletal muscle research 
applications, the data can serve a wide purpose. However, our in vitro approach 
functions on cost of physiological parameters which can be maintained and controlled 
in in vivo models. Furthermore, although the C2C12 model is suitable to study 
molecular mechanisms, the non-contracting nature of the cells makes it less 
comparable to cardiomyocytes or the isolated perfused heart in terms of ATP demand 
and work performance. Due to the irreversible character of 2-deoxy-D-glucose, which 
traps phosphate as 2-deoxy-D-glucose-phosphate, a reperfusion phase would hamper 
the recovery phase. We therefore decided not to implement a reperfusion phase in this 
model since it would only be a reoxygenation phase and not a true reperfusion. 
Furthermore, due to the tendency of nonviable myotubes to detach from the surface, 
which would be enhanced through any additional change of buffers and washing 
steps, the harvesting of cells for proteins would be inconsistent and could potentially 
result in false positive or false negative results. However, since certain pathways and 
signalling components are only executed at reperfusion, these components could not 
be taken into consideration for the study. Regarding protein extraction, the fact that 
non-viable cells possibly leak enzymes due to a loss in membrane integrity, needs to 
be considered as a disadvantage. The cell lysate sonicated and analysed is therefore a 
mixture of viable and nonviable cells. Additionally, due to the fact that C2C12 cells 
have been differentiated from myoblasts into myotubes, there is a degree of a 
heterogeneous cell population character. The only way of partially compensating for 
that is highly consistent culture work, using the same techniques and using cells at the 
same time points and within the frame of a certain passage number only.  
 
4.2. Cell viability  
 
Our data regarding cell viability verify that the methodology employed for the 
experimental protocol was functional. The ischaemic insult was potent, since 8 hrs 
simulated ischaemia together with the irreversible glycolysis inhibitor, 2-deoxy-
glucose contained in the Esumi buffer, induced an ischaemic event which was 
sufficient to reduce viability significantly after 8 hrs in the SI group (Figure 3.1.1.). 
The cytoprotective effect of 0.5 ng/ml TNF-α was verified and reflected in significant 
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increase in viability compared to SI. Also, the capacity of the cells used in the 
experiment, to be classically preconditioned, was shown in their increased viability, 
reaching significance when compared to SI. Although there was no significant 
difference between the degree of protection in the two preconditioning groups, IPC 
and TNF-α PC, a tendency towards a greater cytoprotective effect could be observed 
in TNF-α PC. The selective cPLA2 inhibitor, AACOCF3, also induced significant 
cytoprotection (Figure 3.1.1.). However, the degree of this cytoprotection was not 
modulated, when using AACOCF3 in the presence of 0.5 ng/ml TNF-α.  
 
Observations made in several studies are in agreement with these findings, and 
attribute a cytoprotective effect to cPLA2 inhibition, depending however, on model 
and cell type employed. In a cerebral ischaemia cPLA2-/- knock out mice model, a 
significant reduction in brain infarct volume was shown compared to cPLA2+/+ wild 
type mice (Sapirstein and Bonventre, 2000). Global ischaemia and the high 
intracellular levels of free Ca2+ resulting from ischaemic membrane depolarisation 
and opening of Ca2+ channels were mentioned as factors to trigger cPLA2 activation 
(Kramer and Sharp, 1997). Due to alterations in physicochemical properties of the 
cellular membranes in the ischaemic event, the phospholipid containing membranous 
structures are made more vulnerable to cPLA2 activity. Kriem et al. (2005) 
demonstrated that in rat cortical neurons, when treated with cPLA2 antisense 
oligonucleotides and a selective inhibitor of cPLA2 activity, AA release was abolished 
and cells were protected from apoptosis induced by the amyloid peptide Aβ. 
Furthermore, the use of inhibitors of ERK and p38, also reduced Aβ induced cell 
death (Kriem et al., 2005).   
 
In context of the myocardium, although also highly susceptible to an ischaemic insult, 
we find conflicting results regarding the role of cPLA2. There is evidence that 
alterations in the cPLA2 activity are able to modulate myocardial AA levels and that 
the extent of AA accumulation is proportional to the degree of underperfusion or 
ischaemia (Van der Vusse et al., 1997). Many suggestions have been made to link the 
cPLA2-induced AA generation with cardiac function and ischaemic tolerance.  
Peroxidized metabolites of AA could exert inherent toxic effects. It has been shown 
that the enzymes that metabolize AA produce reactive oxygen species (Burton et al., 
1990). This is contextually important since the production and release of reactive 
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oxygen species produced in ischaemia and reperfusion induce peroxidation of lipid 
membranes, which in turn increases their susceptibility to the action of cPLA2. This 
would also imply that the recruitment of the inflammatory pathway is detrimental in 
this context. Furthermore, AA administration has been shown to  affect the amplitude 
of the Ca2+ transient in cardiac myocytes and reduced the contraction rate (Van der 
Vusse et al., 1997). These AA-linked observations could explain the mechanism of 
AACOCF3 induced cytoprotection in ischaemia, inducing a shift from the 
inflammatory pathway. On the other hand, it has been reported that external AA 
administration to ischaemic neonatal cardiomyocytes provides cytoprotection 
(Engelbrecht et al., 2005). Gottlieb and co-workers (2002) have shown in the isolated 
rat heart model, that the calcium independent phospholipase A2 (iPLA2) is detrimental 
to the heart and that inhibition of iPLA2 confers cardioprotection. However, 
employing the cPLA2 inhibitor AACOCF3 in that model, no cardioprotection was 
observed and it was proposed that cPLA2 is not involved in ischaemia/reperfusion 
injury. On the other hand, when sepsis is induced and cPLA2 measured in the rat 
heart, a 60% cPLA2 activity increase was observed during late sepsis, which was 
related to organ function and mortality (Tong et al., 1998).  
 
These conflicting results could be explained by a differential tissue cPLA2 
bioavailability. It has been suggested that the overwhelming majority of measurable 
phospholipase A2 activity in the heart is the calcium-independent iPLA2 isoform 
(McHowat and Creer, 2004). A 10-fold induction of iPLA2 during a brief episode of 
myocardial ischaemia has been reported (Hazen et al., 1991). In fact, the complexity 
of the signalling cascade and the mechanism for cPLA2 activation is further 
complicated by the overlapping expression of multiple PLA2 enzymes with 
interdependent actions within the cell. Thus, it has been suggested that cPLA2 might 
be important in modulating the activity of iPLA2 (McHowat and Creer, 2004). In this 
context it needs to be mentioned that AACOCF3 is not totally specific to cPLA2, but 
also potentially inhibits iPLA2. However, it exhibits a 500-fold greater potency 
against cPLA2 than against iPLA2. The inhibition is likely to be highly complex due 
to the inter-dependent relationship.  
 
The cytoprotective effects seen with TNF-α PC in this model are in agreement with 
recent studies. Although there are minor differences in the extent of protection we 
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observed, compared with data from available literature, this might be attributed to the 
heterogeneous character of the C2C12 cell line, culture media composition, the 
percentage of O2 in the hypoxic chamber and the discrepancies in the time needed to 
achieve this hypoxic environment.  
 
How can the protective mechanism seen with TNF-α PC be explained? The 
expression of low concentrations of TNF-α for relatively short periods of time 
provides the heart with a short term adaptive response to stress. The same is highly 
likely to be applicable to skeletal muscle tissue. These patterns are mirrored when 
preconditioning the heart with a low dosage of TNF-α for a short time period. Despite 
the capacity of  TNF-α to function as an ischaemic preconditioning  mimetic, a dose 
dependent effect of TNF-α determined the outcome of tissue tolerance to ischaemia 
(Lecour et al., 2002). Using recombinant TNF-α as preconditioning stimulus, a dose 
of 0.5 ng/ml TNF-α was most beneficial in myocardial infarct size reduction 
following the ischaemic event (Lecour et al., 2002).  
 
The fact that TNF-α contributes to cardiac dysfunction and cardiomyocyte death in 
I/R injury has led to the investigation of several molecular role players. It has been 
suggested that H2O2-induced p38 MAPK activation may be involved in the TNF-α 
generation via the activation of NFκB. It was reported that p38 MAPK contributes to 
TNF-α production during I/R and that inhibition of p38 MAPK attenuates TNF-α 
production and mitochondrial damage (Kimura et al., 2006).  NFκB itself is becoming 
apparent in the pathophysiology of I/R injury and ischaemic preconditioning, since it 
can be activated by reactive oxygen species and cytokines. In that way TNF-α can 
induce NFκB activation, which in turn is able to induce TNF-α gene transcription 
(Valen et al., 2001). On the other hand it has been shown that in the context of TNF-α 
mediated cytoprotection, p38-MAPK activation does not contribute to 
cardioprotection. TNF-α- induced phosphorylation of p38-MAPK was detected only 
in the non-cardioprotective TNF-α concentrations (Tanno et al., 2003). In the setting 
of anesthetized rabbits it was shown that antibodies against TNF-α, when given one 
hour before coronary artery occlusion, were as effective as ischaemic preconditioning 
in reducing the infarct size. The treatment also abolished the increase in circulating 
TNF-α levels (Belosjorow et al., 2003). 
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Our results show no significant differences in viability between IPC and TNF-α PC. 
The literature suggests that IPC and TNF-α signalling are interlinked via adenosine. It 
has been shown that adenosine´s anti-inflammatory effects include a decrease in 
cardiac TNF-α production following I/R injury, as well as the inhibition of neutrophil 
adhesion to cardiac myocytes (Meldrum, 1998). Ischaemic preconditioning or 
adenosine stimulation decreased myocardial TNF-α production and improved post-
ischaemic functional recovery. These observations suggested a distal effector role for 
TNF-α production (Meldrum et al., 1998). Cardioprotection by ischaemic 
preconditioning is associated with reduced TNF-α production during I/R (Belosjorow 
et al., 1999). When preconditioning is performed with TNF-α, the preconditioning 
mimetic downregulates its own production. Using TNF-α null (TNF-α -/-) mice , it has 
been shown that cardiac TNF-α production is a necessity for cardioprotection induced 
by IPC, substantiating a key role of TNF-α in the IPC cascade.  Furthermore, 
administration of a low dose  recombinant TNF-α mimicked IPC in wild-type mice, 
but not in the TNF-α deficient species (Smith et al., 2002). Some of these findings are 
of course not applicable to the cell culture model used, since here, all systemic effects 
are excluded. Furthermore, in our viability study one cannot differentiate the 
contribution of necrosis or apoptosis towards cell death. However, the trypan blue 
method used in this protocol is based on cellular plasma membrane integrity and 
function, challenging the exclusion of trypan blue. This mechanism might be more 
related to necrotic than apoptotic cell death, where the membrane integrity is 
maintained.  
 
TNF-α-induced cytoprotection from ischaemia has also been shown to occur in other 
tissues. In neurons it has been shown that TNF-α plays a key role in the ischaemic 
tolerance induced by ischaemic preconditioning and it was proposed that the 
sphingolipid, ceramide, is a mediator for this tolerance (Liu et al., 2000). In context of 
focal cerebral ischaemia, TNF-α was able to induce significant protection against 
ischaemic brain injury, when used in a low dose (0.5 µg/mouse) as pre-treatment 
(Nawashiro et al., 1997). Low dose TNF-α pre-treatment prior to hepatic ischaemia 
has also shown to protect hepatocytes with substantially reduced liver injury (Teoh et 
al., 2003). The sphingomyelin-ceramide signalling pathway is also activated in 
response to I/R injury. This is of interest, since sphingomyelinases are activated via 
the high affinity TNFR1. Resulting ceramide accumulation is implicated in the 
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production of free radicals, but has been shown to also exhibit a protective role 
against ischaemic injury (Levade et al., 2001). Others have shown that the infarct 
limiting effect seen in TNF-α preconditioning was abolished when using a ceramidase 
inhibitor and that the C2-ceramide itself was able to mimic the preconditioning effect 
(Lecour et al., 2002).  
 
To substantiate the role of free radicals, it has been shown that when preconditioning 
with TNF-α, free radical release was substantially increased with the protective low 
dose, and that the protection was abolished when using a potent antioxidant (Lecour et 
al., 2005) . It has been suggested that both ischaemic and TNF-α preconditioning are 
converging at the mitochondria level, the likely source of oxygen radical synthesis 
(Lecour et al., 2002). Another study showed that TNF-α pre-treatment causes a 
biphasic increase of ceramide levels and a cellular failure to up-regulate intercellular 
adhesion molecule 1 (ICAM-1), critical for leukocyte transmigration to the site of 
inflammation and injury (Ginis et al., 1999). This would suggest a role of 
inflammation inhibition in the context of TNF-α mediated cytoprotection.  
 
4.3. Apoptosis and cPLA2 phosphorylation 
 
A significant downregulation of cPLA2 in the TNF-α PC group was observed after 8 
hrs ischaemia (Figure 3.1.2.). However, a similar degree of cPLA2 phosphorylation 
was observed in the SI group. Although there is evidence that TNF-α can regulate 
cPLA2 (Amadou et al., 2002), this does not seem to be the case in our model. This is 
most probably due to the major variations in the cell types employed in the studies 
involved. Furthermore, in rat ventricular myocytes a TNF-α-induced stimulation of 
different PLA2 isoforms has been demonstrated, and it is known that different tissues 
show a differential phospholipase profile (Liu and McHowat, 1998). It is interesting 
that in our study, IPC completely reduces cPLA2 phosphorylation, reaching statistical 
significance compared to the SI group (Figure 3.1.2.). Similar results are seen when 
employing the caspase inhibitor Z-DEVD-FMK. Z-DEVD-FMK is an irreversible 
cell-permeable inhibitor of caspase-3, -6, -7, and -8. However, when using the 
inhibitor in the presence of 0.5 ng/ml TNF-α, the observed inhibition was overridden, 
resulting in a significantly higher degree of cPLA2 phosphorylation. According to the 
protein band pattern, we do not find any indication for cPLA2 cleavage. Total cPLA2 
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levels were constant and no additional bands of lower molecular weight, which 
indicate cleaved protein fragments, were observed. Thus, our results do not conform 
with the proposed mechanism of caspase induced cPLA2 cleavage (Kronke and 
Adam-Klages, 2002). The multiple cleavage sites on cPLA2 for various caspases 
would ensure its cleavage, avoiding the induction of the inflammatory pathway and 
assuring apoptosis. Indeed, it has been shown that cleavage of cPLA2 results in the 
inactivation of its enzymatic activity (Kronke and Adam-Klages, 2002).  In TNF-α 
stimulated HEK cells an increase in cPLA2 activity was seen after caspase-3 
inhibition, suggesting a role for caspases to downregulate or terminate cPLA2 
activation. This could explain the observed increased viability seen when employing 
the AACOCF3 inhibitor. However, as discussed at a later stage, our images suggest 
that a differential translocation pattern is associated with the TNF-mediated 
cytoprotection, mediating a functional cPLA2 inhibition, and thus inhibiting the 
inflammatory pathway.  
 
It can be seen in the caspase-3 cleavage pattern, that the apoptotic pathway in our 
model, following 8 hrs ischaemia, is activated (Figure 3.1.3.). As anticipated, the 
caspase inhibitor significantly decreased caspase-3 cleavage, but it was overidden 
when co-incubating with TNF-α. However, TNF-α PC shows a significantly higher 
degree of caspase-3 cleavage than IPC. Viability investigations will help to 
interpretate these findings in context. This is of importance, since the apoptotic 
pathway, though activated, is not necessarily executed. Thus, the induction of 
apoptosis could increase the chance of cell survival, as long as the pathway is still 
reversible. This phenomenon could function similarly to IPC, namely buying out 
lethal time. The only challenge remains, is to dissect out the time frame when 
ischaemic injury is still reversible.  
 
Our western blot results show, that caspase-3 cleavage is induced during SI (Figure 
3.1.3.). It has been proposed that apoptosis may be the prominent form of ischaemia-
related cell death in the heart. This, however, should only make sense at the onset of 
ischaemia, when one considers the extremely high ATP demand in the myocardium, 
which would lead to rapid ATP depletion and would cause a shifts towards necrosis 
induction (Clerk et al., 2003). It would be highly feasible for the ischaemically 
challenged cell to extend and maintain the apoptotic pathway and thereby increasing 
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the chance of apoptosis reversibility upon reperfusion. It was verified in a TNF-α 
resistant L929 cell line, deficient in cPLA2, that cPLA2 plays a key role in TNF- α-
induced apoptosis. When cPLA2 expression was induced, the TNF- α response could 
be restored (Taketo and Sonoshita, 2002). It was also recently shown by Fu and co-
workers (2004) that TNF-α reduction in the cardiomyocyte could have an impact on 
the caspase-3 pathway, and when employing neutralizing anti-TNF-α antibodies, 
norepinephrine induced apoptosis was attenuated (Fu et al., 2004).  
 
As discussed in chapter one, cleaved caspase-3 is able to cleave the enzyme PARP. 
The signal for the intact 116 kDa PARP molecule was detectable in untreated 
normoxic control cells where the 116 kDa band was strong (Figure 3.1.4.). In treated 
cells, the weak 116 kDa signal indicated PARP cleavage. We observed that the extent 
of caspase-3 cleavage was mirrored by the extent of PARP cleavage, seen in the 
reduction of the total PARP 116 kDa molecule, after 8 hrs ischaemia. This might be 
indicative of the progression of apoptosis induction within the pathway.  
 
Unfortunately the caspase-3 silencing and transfection was not successful, reflected in 
a caspase-3 band similar to that of the control cells (for purposes of documentation, 
Figure 3.1.5. is included). This is most probably related to the known difficulty in 
transfecting muscle cells, since a transfection reagent applicable for a broad range of 
cells was used. Nevertheless, the western blot results found at the 8 hrs time point and 
the viability data made us decide to investigate the signalling mechanism of cPLA2 
early in the simulated ischaemic event.  
 
4.4. Cellular signalling 
 
It was decided that 5 min and 30 min into the ischaemic event would be the most 
appropriate time points to elucidate signalling events in our cell model, due to the 
likelihood of cPLA2- and MAPK phosphorylation (van Rossum et al., 2004). 
 
To our surprise, we did not find any significant differences regarding cPLA2, p38- and 
ERK phosphorylation at 5 min into ischaemia (Figure 3.2.1., Figure 3.2.2.a./b.). A 
faint banding pattern implies a very small degree of cPLA2 phosphorylation under 
control conditions. We also observed a faint and non-significant pERK and pp38 
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signal in the control cells, which could be attributed to the serum-containing culture 
medium (van Rossum et al., 2001). It has been shown that  the mechanisms involved 
in the regulation of cPLA2 such as the phosphorylation, calcium concentration and 
site of subcellular location appear to be cell-type and agonist-dependent (Gijon et al., 
1999). The differences in potency and effect of the simulated ischaemic event might 
account for these findings. We also could not describe an effect of the cPLA2 inhibitor 
on the phosphorylation state of these kinases. Furthermore, we did not observe 
significant changes in the caspase-3- or PARP cleavage pattern (Figure 3.2.3.a./b.). 
 
We still did not see any changes in the cPLA2 phosphorylation pattern at 30 min into 
the ischaemic event (Figure 3.3.1.). This is surprising since other data suggest 
phospholipase activation early in ischaemia. It has been shown that ischaemia affects 
phospholipid metabolism in a profound way, with increasing susceptibility of 
phosphatidylcholine synthesis, in the isolated rat heart model (Lochner and de 
Villiers, 1989). Here it was demonstrated, that already within 10 min, the 
incorporation rate of (methyl-3H) choline into tissue phospholipids was significantly 
inhibited, whereas tissue choline levels remained the same (Lochner and de Villiers, 
1989).  
 
Although there was an increase in ERK phosphorylation in the IPC and TNF-α PC 
groups compared with Con and SI, it was not significant. Also, the cPLA2 inhibitor, 
AACOCF3, caused a significant increase in ERK phosphorylation, compared to 
control values (Figure 3.3.2.a.). This is in agreement with our viability results, since 
ERK is known to mediate survival signals in the cell (Burgering and Bos, 1995). 
Several studies indicated a role for ERK in IPC (Omura et al., 1999; Liu et al., 2003). 
In response to a preconditioning stimulus, ERK has been shown to translocate to the 
nucleus, where it has been demonstrated to activate NFkB and AP-1 (Hobbie et al., 
1997; Hausenloy and Yellon, 2006). Activation of ERK-1/2 at reperfusion, following 
a prolonged ischaemic event, protects the heart against ischaemia/reperfusion injury 
(Hausenloy et al., 2004). However, in the context of TNF-α PC, it has been shown 
that ERK activation in the early reperfusion phase is not essential for TNF-α induced 
preconditioning (Lecour et al., 2005).  
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Unexpectedly, our results indicated a significant increase in p38 phosphorylation only 
in the IPC group, with a trend towards increased p38 phosphorylation in the TNF-α 
PC group (Figure 3.3.2.b.). This is in agreement with results from Weinbrenner et al. 
(1997), who showed that p38 MAPK activation correlates with the protection induced 
by preconditioning in rabbit hearts (Weinbrenner et al., 1997). Furthermore, 
attenuation of p38 MAPK activation during ischaemia and during reperfusion was 
associated with improved functional recovery during reperfusion (Marais et al., 
2001). p38 MAPK activation has been shown to be induced by a multi-episode 
preconditioning protocol which was associated with a significant reduction in p38 
MAPK activation at global ischaemia and at reperfusion, compared with the marked 
activation observed in untreated non-preconditioned hearts. In many cell types p38 
also appears to enhance apoptosis (Park et al., 2000).  
 
At 30 min into ischaemia we do not observe significant changes in the caspase-3 or 
PARP cleavage pattern (Figure 3.3.a./b.). However, the trend already observed at the 
5 min time point, with a lower signal of cleaved caspase-3 in the control and SI group, 
is mirrored also at 30 min. 
 
4.5. Immunocytochemistry at 30 min into simulated ischaemia 
 
4.5.1. cPLA2 translocation 
 
A functional phospholipid bilayer system such as the sarcolemma is crucial to 
maintain cellular function. Not only is the intact cell membrane needed to control ion 
homeostasis, but membrane integrity is also necessary to provide an optimal receptor 
platform, with a defined membrane fluidity to allow optimal receptor mediated 
pathway interactions. Another important role of phospholipid bilayers is their 
contribution to subcellular organelle membranes, such as mitochondria, the 
endoplasmic reticulum (ER), the Golgi apparatus or the nuclear network, contributing 
to a functional compartmentalization within the cell. The subcellular membranes 
provide a microenvironment needed for each organelle to fulfil its specific function. 
Via hydrolization of fatty acyl moieties of membrane phospholipids through extensive 
actions of cPLA2, this environment would be disturbed, and its optimal functional 
capacity reduced.  
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However, an ischaemically challenged cell undergoing necrosis loses its membrane 
integrity, with detrimental consequences for the cellular environment. One important 
role player in this context is the activation of phospholipases and specifically cPLA2, 
as it  has been suggested as a likely candidate in the pathogenesis of ischaemia and 
reperfusion injury (Van der Vusse et al., 1997). Membrane-associated enzyme 
systems such as the ATP-dependent Ca2+ transporter can be impaired due to the 
activation of cPLA2 (Tong et al., 1998).   
 
We, therefore, investigated the translocation pattern of cPLA2 at 30 min into the 
ischaemic event, a relevant time point as it allows time to provide stimulatory signals 
for cPLA2 activation (van Rossum et al., 2004). Our results show that in untreated 
normoxic control cells, staining for pcPLA2 resulted in a fine punctuate labelling 
pattern randomly distributed throughout the cytoplasm of the myotube, with a fine 
pattern in the nucleus. The random nature of the distribution was supported by the fact 
that optical z-sections revealed the pattern in all depths in the cell. However, in SI a 
significant increase in mean nuclear intensity is observed, indicating cPLA2 
translocation to the nucleus and peri-nuclear region. Both the IPC and TNF-α PC 
group showed a significant increase in nuclear intensity compared to control levels;  
however these were significantly less than in the SI group. These findings were 
verified using two different analysis techniques and different labelling techniques. 
Our z-stack-based analyses showed that intranuclear speckles are present, with the 
highest fluorescence intensity seen in SI, suggesting an association of cPLA2 with 
invaginations of the nuclear membrane (Grewal et al., 2005). In context of the 
inflammatory pathway, enzymes such as COX, which are situated downstream of 
cPLA2, and which are involved in eicosanoid synthesis, are localized in the nuclear 
membrane region (Murakami et al., 2003). An emerging body of evidence suggests 
that the spatio-temporal co-localization of eicosanoid-biosynthetic enzymes in the 
perinuclear region is critical for their effective functional coupling (Pardue et al., 
2003). COX-1 is generally considered as a house keeping enzyme that is 
constitutively expressed and involved in homeostasis. The inducible COX-2, on the 
other hand, is expressed primarily in disease states and in response to inflammation. 
Both isoforms have been shown to localize at the nuclear envelope and endoplasmic 
reticulum (Grewal et al., 2005). It is thought that the liberation of free AA is rate 
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limiting for the synthesis of these mediators. Furthermore,  AA release has been found 
to be proportional to the extent of cPLA2 translocation and to the Ca2+ concentration 
in the cell (Szabo and Dawson, 1998).  
 
It can therefore be hypothesized that the observed translocation of cPLA2 to the 
nuclear region leads to AA generation and functional enzyme coupling, leading to the 
generation of inflammatory mediators. Furthermore, due to the differential 
translocation response seen in our results one can expect a differential enzyme 
induction and metabolite accumulation. This in turn is critical in subcellular loci such 
as the perinuclear region and could lead to alterations in subcellular membrane 
molecular dynamics, thus precipitating membrane dysfunction (Hazen et al., 1991). 
Our results imply that IPC and TNF-α PC inhibit cPLA2 relocation, keeping it to a 
large extent in the cytoplasmic compartment and therefore possibly inhibiting 
functional cPLA2 activity (Figure 3.5.1.c.). These findings imply that both TNF-α PC 
and IPC lead to a decrease in inflammatory mediator production, and hence a shift 
away from the inflammatory pathway. This might contribute to the cytoprotective 
effect observed in these groups.  
 
The results clearly indicate that the sarcolemmal membrane per se is not involved as 
target phospholipid bilayer for cPLA2 under ischaemic conditions, but rather that 
phospholipid components in the nuclear envelope and network region are favoured. 
Interestingly, the intermediate filament vimentin has been suggested to serve as 
functional adapter for cPLA2, acting as a scaffold protein and assisting in appropriate 
interactions between cPLA2 and perinuclear phospholipids membranes to stabilize the 
binding of cPLA2 to the membrane (Murakami et al., 2000). That the target organelle 
is crucial in terms of cellular outcome has been shown in several studies (Evans et al., 
2001). Bunt and co-workers (1997) showed a similar punctuate labelling pattern of 
cPLA2 in fibroblasts under normoxic conditions (Bunt et al., 1997). Others (Herbert et 
al., 2005) have shown that cPLA2 activity and function in controlling endothelial cell 
proliferation is regulated by reversible association with the Golgi apparatus.  
 
Differential Ca2+ dependent membrane targeting of cPLA2 has been described with 
various intracellular organelles, including the ER, the perinuclear region and  the 
Golgi apparatus (Evans et al., 2001). It is of interest to try to explain this differential 
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cPLA2 translocation pattern in our cell model. It is known that under ischaemic 
conditions the Ca2+ handling capacity of the cell is impaired (Hearse, 1994). Ca2+ is 
the crucial activation stimulus for cPLA2 (Clark et al., 1995). The observed 
translocation pattern could therefore be an indicator for the cell’s Ca2+ handling 
capacity. Preconditioning has been described as a mechanism to lessen calcium-
mediated damage (Opie, 1997). There are also data available which show that TNF-α 
can modulate the sarcoplasmic reticulum Ca2+ release and Ca2+ transients in the 
ischaemic myocardium (Meldrum et al., 1998). cPLA2 modulates ER calcium 
handling and might contribute to ineffective calcium sequestration by the  
sarcoplasmic reticulum, rather than an ineffective sarcolemmal calcium extrusion. 
Since the same reduction in cPLA2 translocation is seen in IPC, better calcium 
handling might functionally inhibit cPLA2 and thus contribute to the increased 
viability seen in IPC, TNF-α PC as well as after treatment with the cPLA2 inhibitor, 
AACOCF3. In the sarcoplasmic reticulum and other subcellular regions, energy 
dependent mechanisms take place, such as the activity of ATP dependent Ca2+-
ATPase. These mechanisms would be impaired in ischaemia due to the decrease in 
ATP availability, contributing to impaired Ca2+ homeostasis. On the other hand, in 
this model no contraction takes place as in the case of cardiomyocytes, so the Ca2+ 
dependency and ATP demand differ. However, it can only be speculated whether 
these mechanisms play a role in our cell model.  
 
4.5.2. cPLA2 co-localization 
 
z-stack experiments are a necessity for co-localization studies, since unlike in a 
conventional two-dimensional image overlay, all three spatial dimensions are 
considered and this enables a true calculation for co-localization. For verification of 
cPLA2 nuclear translocation, the nuclear marker nucleoporin p62 was used and co-
labelled with pcPLA2.  The results show differential co-localization with the 
significantly largest co-localization area in the SI group compared to the control cells. 
Co-localization area in IPC and TNF-α PC was significantly smaller compared to the 
SI group. These results indirectly mirror the cPLA2 translocation results described 
above, and substantiate the observed differential nuclear preference.  
 
 104
Interestingly, after careful image analysis we observed, only in the SI group, a 
different and distinct strong clustered cPLA2 pattern in the cytoplasm. We, therefore, 
labelled the myotubes for the endoplasmic reticulum (ER) marker calnexin. The 
images resulted in a similar punctuate cluster pattern, providing preliminary and novel 
evidence for a distinct and differential target organelle for cPLA2 in SI, namely the 
ER in addition to the nuclear region.   
 
4.6. Conclusion and future directions 
 
The results provide evidence that there is a role for cPLA2 signalling in TNF-α 
mediated cytoprotection. The aim of the study was to investigate the kind of cPLA2 
involvement, its cellular activation, translocation and degradation, and thus turnover 
in TNF-α PC.  
 
Although we did not observe a differential activation pattern in TNF-α PC in terms of 
cPLA2 phosphorylation and no differential inactivation of cPLA2 via cleavage, we 
describe a differential cPLA2 translocation pattern, similar to that in IPC. We 
hypothesize that through inhibition of cPLA2 translocation a potential functional 
cPLA2 inhibition is achieved. This would imply inhibition of the inflammatory 
pathway, subsequently less generation of inflammatory mediators and a shift away 
from the inflammatory pathway (Figure 4.6.). Such a mechanism would allow more 
time for cellular decision making, which otherwise would have been spent committing 
to irreversible necrotic cell death. 
 
In conclusion, we provide evidence to indicate that TNF-α preconditioning is 
associated with distinct cPLA2 signalling which may be an important component in 
the cascade of events in channelling the production of injurious mediators in 
inflammation. These findings can provide new ideas in the context of inflammation 
treatment through agents which control differential cPLA2 trafficking within the cell. 
Understanding the mechanisms underlying these processes has the potential to extend 
current strategies and to identify new ones to treat cardiac disease. Ischaemic 
preconditioning has not materialized in the clinic because of the prerequisite for it to 
be applied prior to the onset of index ischaemia or myocardial infarction, which is  
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Figure 4.6. Proposed mechanism of cPLA2 associated pathway induction between 
inflammatory and apoptotic pathway, associated with the extent of cytoprotection.  
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unlikely to be predictable. However, new strategies employing the growing body of 
knowledge generated in the field of IPC have recently emerged, which led to the 
introduction of the post-conditioning concept (Tsang et al., 2004; Yellon and 
Hausenloy, 2005; Yellon and Opie, 2006). This could also be beneficial in the context 
of TNF-α preconditioning, providing room for translation of current knowledge into a 
clinically more relevant context. For example, a longer-termed TNF-α treatment in 
addition to standard preventative therapy could be used in conditions of ischaemic 
heart disease and heart failure, to prevent the development of a beneficial 
environment for inflammation. At the same time this could provide a protective 
window for a possible future ischaemic event, a fact which is even more desirable, 
since a weakened and infarcted myocardium is already exposed to a higher level of 
stress and is shifted out of its homeostatic balance.   
 
For future experiments it would be of great benefit to employ novel techniques to be 
able to generate data which accurately reflect the real scenario in the ischaemically 
challenged cell or tissue. It is also necessary to identify the downstream events 
following cPLA2 activation, like target proteins or metabolic pathways for the 
liberated AA or other fatty acids. Furthermore, the recruitment of human cells or 
tissues is suggested, to exclude species dependent discrepancies. For example, the fact 
that there are double the number of phosphorylation sites in human cPLA2 compared 
with murine cPLA2, might contribute to a much greater degree of control in the 
mechanism of cPLA2 activity, possibly with a steeper gradient of recruitable activity 
(Kramer and Sharp, 1997). Using live cell dyes for relevant cellular organelles such as 
the ER-tracker or mito-tracker, questions about AA induced ROS production can be 
addressed under real time conditions. In this context, ion fluorophores such as Fura 
could be employed to investigate the previously discussed cellular Ca2+ handling 
capacity under real time ischaemic conditions. This will shed more light on the 
survival mechanisms employed by the ischaemically challenged cell in a setting of 
TNF-α mediated cytoprotection.  
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